Pasar al contenido principal

GRANZIMAS EN LA FISIOPATOLOGIA DE LA SEPSIS VIRAL Y BACTERIANA: PAPEL EN LA INFLAMACION AGUDA Y EN LA PARALISIS INMUNE E INFECCIONES SECUNDARIAS

PID2020-113963RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE ZARAGOZA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 51
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Broad Protection against Invasive Fungal Disease from a Nanobody Targeting the Active Site of Fungal β-1,3-Glucanosyltransferases

  • Redrado-Hernández, Sergio
  • Macías-León, Javier
  • Castro-López, Jorge
  • Belén Sanz, Ana
  • Dolader, Elena
  • Arias, Maykel
  • González-Ramírez, Andrés Manuel
  • Sánchez-Navarro, David
  • Petryk, Yuliya
  • Farkaš, Vladimír
  • Vincke, Cécile
  • Muyldermans, Serge
  • Garcia-Barbazan, Irene
  • Del Agua, Celia
  • Zaragoza, Oscar
  • Arroyo, Javier
  • Pardo, Julián
  • Gálvez, Eva M
  • Hurtado-Guerrero, Ramon
  • Redrado-Hernández, Sergio
  • Macías-León, Javier
  • Castro-López, Jorge
  • Belén Sanz, Ana
  • Dolader, Elena
  • Arias, Maykel
  • González-Ramírez, Andrés Manuel
  • Sánchez-Navarro, David
  • Petryk, Yuliya
  • Farkaš, Vladimír
  • Vincke, Cécile
  • Muyldermans, Serge
  • Del Agua, Celia
  • Zaragoza, Oscar
  • Arroyo, Javier
  • Pardo, Julián
  • Gálvez, Eva M
  • Hurtado-Guerrero, Ramon
Invasive fungal disease accounts for about 3.8 million deaths annually, an unacceptable rate that urgently prompts the discovery of new knowledge-driven treatments. We report the use of camelid single-domain nanobodies (Nbs) against fungal β-1,3-glucanosyltransferases (Gel) involved in β-1,3-glucan transglycosylation. Crystal structures of two Nbs with Gel4 from Aspergillus fumigatus revealed binding to a dissimilar CBM43 domain and a highly conserved catalytic domain across fungal species, respectively. Anti-Gel4 active site Nb3 showed significant antifungal efficacy in vitro and in vivo prophylactically and therapeutically against different A. fumigatus and Cryptococcus neoformans isolates, reducing the fungal burden and disease severity, thus significantly improving immunocompromised animal survival. Notably, C. deneoformans (serotype D) strains were more susceptible to Nb3 and genetic Gel deletion than C. neoformans (serotype A) strains, indicating a key role for β-1,3-glucan remodelling in C. deneoformans survival. These findings add new insight about the role of β-1,3-glucan in fungal biology and demonstrate the potential of nanobodies in targeting fungal enzymes to combat invasive fungal diseases.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inflammatory cell death induced by cytotoxic lymphocytes: a dangerous but necessary liaison

  • Miguel, Diego de
  • Ramírez-Labrada, Ariel
  • Uranga Murillo, Iratxe
  • Hidalgo, Sandra
  • Santiago, Llipsy
  • Gálvez Buerba, Eva Mª
  • Arias, Maykel
  • Pardo, Julián
2 figures., Cytotoxic lymphocytes (CLs), and more specifically Tc and NK cells, are the main executors of cell death in the immune system, playing a key role during both immunosurveillance and immunotherapy. These cells induce regulated cell death (RCD) by different mechanisms, being granular exocytosis and expression of death ligands the most prominent and best characterized ones. Apoptosis, a traditionally considered low-inflammatory type of cell death, has been accepted for years as the paradigm of RCD induced by CLs. However, several recent studies have demonstrated that NK cells and Tc cells can also induce more inflammatory forms of cell death, namely, necroptosis, pyroptosis, and ferroptosis. Activation of these highly inflammatory types of cell death appears to critically contribute to the activation of a successful antitumour immune response. Additionally, the role of specific cell death pathways in immunogenic cell death is still under intense debate, especially considering the interconnections with other inflammatory forms of cell death. These evidences, together with the advent of new cancer immunotherapies, highlight the necessity to deepen our understanding of the link between the cell death triggered by CLs and inflammation. This knowledge will be instrumental to maximize the antitumour potential of immunotherapies, minimizing deleterious effects associated with these treatments. In this review, we will briefly summarize the main features of apoptosis, necroptosis, pyroptosis and ferroptosis, to subsequently discuss the most recent evidences about the role of these RCD pathways during the elimination of cancer cells mediated by CLs and its modulation to increase the efficacy of cancer immunotherapy., Work in the JP laboratory is funded by the FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón, Group B29_17R), Ministerio de Ciencia, Innovación e Universidades (MCNU), Health National Institute Carlos III, Agencia Estatal de Investigación (SAF2017-83120-C2-1-R; PID2020-113963RB-I00), Fundación Inocente Inocente, ASPANOA and Carrera de la Mujer de Monzón. EMG is funded by Agencia Estatal de Investigación (SAF2017-83120-C2-1-R and PID2020-113963RB-I00). DDM is supported by a postdoctoral fellowship ‘Sara Borrell’, LS by a PhD fellowship (FPI) from the Ministry of Science, Innovation and Universities. IUM and SH are supported by a PhD fellowship from Aragon Government. MA is supported by a postdoctoral fellowship ‘Juan de la Cierva-formación’ from the Ministry of Science, Innovation and Universities, and JP is supported by the ARAID Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integration of in silico and in vitro analysis of gliotoxin production reveals a narrow range of producing fungal species

  • Redrado, Sergio
  • Esteban, Patricia
  • Domingo, María Pilar
  • López Gómez, Concepción
  • Rezusta, Antonio
  • Ramírez-Labrada, Ariel
  • Arias, Maykel
  • Pardo, Julián
  • Gálvez Buerba, Eva Mª
5 figures, 3 tables.-- Supplementary information available., Gliotoxin is a fungal secondary metabolite with impact on health and agriculture since it might act as virulence factor and contaminate human and animal food. Homologous gliotoxin (GT) gene clusters are spread across a number of fungal species although if they produce GT or other related epipolythiodioxopiperazines (ETPs) remains obscure. Using bioinformatic tools, we have identified homologous gli gene clusters similar to the A. fumigatus GT gene cluster in several fungal species. In silico study led to in vitro confirmation of GT and Bisdethiobis(methylthio)gliotoxin (bmGT) production in fungal strain cultures by HPLC detection. Despite we selected most similar homologous gli gene cluster in 20 different species, GT and bmGT were only detected in section Fumigati species and in a Trichoderma virens Q strain. Our results suggest that in silico gli homology analyses in different fungal strains to predict GT production might be only informative when accompanied by analysis about mycotoxin production in cell cultures., This research was funded by CIBER -Consorcio Centro de Investigación Biomédica en Red-(CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea –NextGenerationEU, FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón (Group B29_20R), Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (SAF2017-83120-C2-1-R; PID2020-113963RB-I00), ASPANOA, GILEAD (GLD18/00100), Donación Javier Saura Carceller, and Carrera de la Mujer de Monzón. J.P. was supported by Fundacion Aragon I+D (ARAID). P.E.was supported by Fondo Garantıa Empleo Juvenil/INAEM. S.R. was granted funding by a DGA predoctoral contract. M.A. was granted funding by a Juan de la Cierva contract of Spanish Ministry of Economy and Competitiveness (IJC2019-039192-I). M.P.D. was supported by PTA2019-016739-I/MCIN/AEI/10.13039/501100011033., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Adoptive NK cell transfer as a treatment in colorectal cancer patients: analyses of tumour cell determinants correlating with efficacy in vitro and in vivo

  • Lanuza, Pilar M.
  • Alonso, M. Henar
  • Hidalgo, Sandra
  • Uranga Murillo, Iratxe
  • García-Mulero, Sandra
  • Arnau, Raquel
  • Santos Vivas, Cristina
  • Sanjuan, Xavier
  • Santiago, Llipsy
  • Comas, Laura
  • Redrado, Sergio
  • Pazo-Cid, Roberto
  • Agustín Ferrández, M. J.
  • Jaime Sánchez, Paula
  • Pesini, Cecilia
  • Gálvez Buerba, Eva Mª
  • Ramírez-Labrada, Ariel
  • Arias, Maykel
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
6 figures., [Background]: Colorectal cancer (CRC) is a heterogeneous disease with variable mutational profile and tumour microenvironment composition that influence tumour progression and response to treatment. While chemoresistant and poorly immunogenic CRC remains a challenge, the development of new strategies guided by biomarkers could help stratify and treat patients. Allogeneic NK cell transfer emerges as an alternative against chemoresistant and poorly immunogenic CRC., [Methods]: NK cell-related immunological markers were analysed by transcriptomics and immunohistochemistry in human CRC samples and correlated with tumour progression and overall survival. The anti-tumour ability of expanded allogeneic NK cells using a protocol combining cytokines and feeder cells was analysed in vitro and in vivo and correlated with CRC mutational status and the expression of ligands for immune checkpoint (IC) receptors regulating NK cell activity., [Results]: HLA-I downmodulation and NK cell infiltration correlated with better overall survival in patients with a low-stage (II) microsatellite instability-high (MSI-H) CRC, suggesting a role of HLA-I as a prognosis biomarker and a potential benefit of NK cell immunotherapy. Activated allogeneic NK cells were able to eliminate CRC cultures without PD-1 and TIM-3 restriction but were affected by HLA-I expression. In vivo experiments confirmed the efficacy of the therapy against both HLA+ and HLA− CRC cell lines. Concomitant administration of pembrolizumab failed to improve tumour control., [Conclusions]: Our results reveal an immunological profile of CRC tumours in which immunogenicity (MSI-H) and immune evasion mechanisms (HLA downmodulation) favour NK cell immunosurveillance at early disease stages. Accordingly, we have shown that allogeneic NK cell therapy can target tumours expressing mutations conferring poor prognosis regardless of the expression of T cell-related inhibitory IC ligands. Overall, this study provides a rationale for a new potential basis for CRC stratification and NK cell-based therapy., Work in the JP laboratory is funded by ASPANOA, CIBER (CB 2021; Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación and Union Europea.NextGenerationEU), Fundacion Inocente, Carrera de la Mujer Monzón, FEDER/Gobierno de Aragón (Group B29_17R), and Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (SAF2017‐83120‐C2‐1‐R and PID2020-113963RB-I00). Predoctoral grants/contracts from Gobierno de Aragon (IU-M and JP) are supported by ARAID Foundation. EG is funded by Ministerio de Ciencia, Innovación y Universidades (MCNU), and Agencia Estatal de Investigación (PID2020-113963RB-I00). MA and LS are funded by Postdoctoral Juan de la Cierva Contract. SR, LC, SH, and IU-M are funded by predoctoral contracts from Aragon Government. PL is funded by FPU predoctoral grants from Ministerio de Ciencia, Innovación e Universidades. Work at the Catalan Institute of Oncology is funded by the entity, the Instituto de Salud Carlos III and Ministerio de Economia y Competitividad, and co-funded by FEDER funds—a way to build Europe (PI20/00767), CIBERESP (grant CB07/02/2005), H2020 grant MoTriColor, and the Agency for Management of University and Research Grants (AGAUR) of the Catalan Government grant 2017SGR723. This work is supported by COST Action CA17118., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells

  • Pesini, Cecilia
  • Hidalgo, Sandra
  • Arias, Maykel
  • Santiago, Llipsy
  • Calvo, Carlota
  • Ocáriz, Maitane
  • Isla, Dolores
  • Lanuza, Pilar M.
  • Agustín Ferrández, M. J.
  • Gálvez Buerba, Eva Mª
  • Ramírez-Labrada, Ariel
  • Pardo, Julián
5 figures.-- Supplementary information available., The contribution of the T cell-related inhibitory checkpoint PD-1 to the regulation of NK cell activity is still not clear with contradictory results concerning its expression and role in the modulation of NK cell cytotoxicity. We provide novel key findings on the mechanism involved in the regulation of PD-1 expression on NK cell membrane and its functional consequences for the elimination of cancer cells. In contrast to freshly isolated NK cells from cancer patients, those from healthy donors did not express PD-1 on the cell membrane. However, when healthy NK cells were incubated with tumor target cells, membrane PD-1 expression increased, concurrent with the CD107a surface mobilization. This finding suggested that PD-1 was translocated to the cell membrane during NK cell degranulation after contact with target cells. Indeed, cytosolic PD-1 was expressed in freshly-isolated-NK cells and partly co-localized with CD107a and GzmB, confirming that membrane PD-1 corresponded to a pool of preformed PD-1. Moreover, NK cells that had mobilized PD-1 to the cell membrane presented a significantly reduced antitumor activity on PD-L1-expressing-tumor cells in vitro and in vivo, which was partly reversed by using anti-PD-1 blocking antibodies. Our results indicate that NK cells from healthy individuals express cytotoxic granule-associated PD-1, which is rapidly mobilized to the cell membrane after interaction with tumor target cells. This novel finding helps to understand how PD-1 expression is regulated on NK cell membrane and the functional consequences of this expression during the elimination of tumor cells, which will help to design more efficient NK cell-based cancer immunotherapies., Work in the JP laboratory is funded by FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_20R), Ministerio de Ciencia, Innovación y Universidades (MCUN), Agencia Estatal de Investigación (SAF2017-83120-C2-1-R; PID2020-113963RBI00), Fundación Inocente Inocente, ASPANOA, and Carrera de la Mujer de Monzón. Postdoctoral Juan de la Cierva Contract (MA and LS) and Predoctoral Grant from AECC (CP). JP is supported by ARAID Foundation; Fundación Agencia Aragonesa para la investigación y el Desarrollo; Fundación Científica Asociación Española Contra el Cáncer., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Silver nanoparticles–polyethyleneimine-based coatings with antiviral activity against SARS-CoV-2: A new method to functionalize filtration media

  • Baselga-Lahoz, Marta
  • Uranga Murillo, Iratxe
  • Miguel, Diego de
  • Arias, Maykel
  • Sebastián, Víctor
  • Pardo, Julián
  • Arruebo, Manuel
The use of face masks and air purification systems has been key to curbing the transmission of SARS-CoV-2 aerosols in the context of the current COVID-19 pandemic. However, some masks or air conditioning filtration systems are designed to remove large airborne particles or bacteria from the air, being limited their effectiveness against SARS-CoV-2. Continuous research has been aimed at improving the performance of filter materials through nanotechnology. This article presents a new low-cost method based on electrostatic forces and coordination complex formation to generate antiviral coatings on filter materials using silver nanoparticles and polyethyleneimine. Initially, the AgNPs synthesis procedure was optimized until reaching a particle size of 6.2 ± 2.6 nm, promoting a fast ionic silver release due to its reduced size, obtaining a stable colloid over time and having reduced size polydispersity. The stability of the binding of the AgNPs to the fibers was corroborated using polypropylene, polyester-viscose, and polypropylene-glass spunbond mats as substrates, obtaining very low amounts of detached AgNPs in all cases. Under simulated operational conditions, a material loss less than 1% of nanostructured silver was measured. SEM micrographs demonstrated high silver distribution homogeneity on the polymer fibers. The antiviral coatings were tested against SARS-CoV-2, obtaining inactivation yields greater than 99.9%. We believe our results will be beneficial in the fight against the current COVID-19 pandemic and in controlling other infectious airborne pathogens, The microscopy works have been conducted in the “Laboratorio de Microscopias Avanzadas (LMA)” at “INMA–University of Zaragoza”. CIBER-BBN is an initiative funded by the VI National R&D&i Plan 2008–2011 financed by the Instituto de Salud Carlos III with the assistance of the European Regional Development Fund. Work in the JP laboratory is funded by FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón (Group B29_17R), Ministerio de Ciencia, Innovación y Universidades (MCNU), Agencia Estatal de Investigación (PID2020-113963RBI00), Fundación Inocente Inocente, ASPANOA and Carrera de la Mujer de Monzón. Postdoctoral Juan de la Cierva Contract (MA) and Sara Borrell contract (DdM) and Predoctoral Grant from Gobierno de Aragon (IUM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fluorogenic Granzyme A substrates enable real-time imaging of adaptive immune cell activity

  • Cheng, Zhiming
  • Thompson, Emily J.
  • Mendive-Tapia, Lorena
  • Scott, Jamie I.
  • Benson, Sam
  • Kitamura, Takanori
  • Senán Salinas, Ana
  • Samarakoon, Youhani
  • Roberts, Edward W.
  • Arias, Maykel
  • Pardo, Julián
  • Gálvez Buerba, Eva Mª
6 figures., Cytotoxic immune cells, including T lymphocytes (CTLs) and natural killer (NK) cells, are essential components of the host response against tumors. CTLs and NK cells secrete granzyme A (GzmA) upon recognition of cancer cells; however, there are very few tools that can detect physiological levels of active GzmA with high spatiotemporal resolution. Herein, we report the rational design of the near-infrared fluorogenic substrates for human GzmA and mouse GzmA. These activity-based probes display very high catalytic efficiency and selectivity over other granzymes, as shown in tissue lysates from wild-type and GzmA knock-out mice. Furthermore, we demonstrate that the probes can image how adaptive immune cells respond to antigen-driven recognition of cancer cells in real time., A. S. acknowledges a PhD fellowship from the Aragon Government. M. A. A. acknowledges funds from the Ministry of Economy and Competitiveness, Spain (IJC2019- 039192-I). This research was supported by CIBER (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU, FEDER (Group B29_20R), Ministry of Science, Innovation and Universities and Agencia Estatal de Investigación, Spain (SAF2017-83120-C2-1-R and PID2020-113963RB-I00). T. K. acknowledges funding from an MRC Career Development Award (MR/S006982/1) and an MRC Centre Grant (MR/N022556/1). E. W. R. acknowledges a Cancer Research UK grant (A_BICR_1920_Roberts). M. V. acknowledges funds from an ERC Consolidator Grant (DYNAFLUORS, 771443) and an ERC PoC Grant (IBDIMAGE, 957535). This project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement (859908)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A subset of PD-1-expressing CD56bright NK cells identifies patients with good response to immune checkpoint inhibitors in lung cancer

  • Gascón, Marta
  • Ramírez-Labrada, Ariel
  • Lastra, Rodrigo
  • Martínez-Lostao, Luis
  • Paño, José Ramón
  • Sesma, Andrea
  • Zapata, María
  • Moratiel, Alba
  • Quílez, María Elisa
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Domingo, María Pilar
  • Esteban, Patricia
  • Gálvez Buerba, Eva Mª
  • Pardo, Julián
  • Isla, Dolores
5 figures, 5 tables.-- Supplementary information available., In recent years, studies in cancer immunotherapy have focused on finding predictive response biomarkers to anticipate which patients will respond to each kind of treatment, optimizing treatment strategy and reducing toxicities and costs. Unfortunately, these studies are still limited, and no conclusive results have been obtained. This study was designed to prospectively analyze a cohort of lung cancer patients receiving immunotherapy attempting to determine cellular biomarkers of response, as T-lymphocyte and natural killer (NK) cell subsets, in peripheral blood. Despite previous studies, none of these populations have been identified yet with clinical relevance to be established in clinical practice. In our study, we have identified a subset of circulating CD56+CD16-PD-1+ NK cells showing a good predictive ability. These results contribute to the development of precision medicine protocols where we could stratify patients according to the expected treatment response to choose the best option for each patient., Despite the effectiveness of immune checkpoint inhibitors (ICIs) in lung cancer, there is a lack of knowledge about predictive biomarkers. The objective of our study is to analyze different subsets of T-lymphocytes and natural killer (NK) cells as predictive biomarkers in a cohort of patients with nonsmall cell lung cancer (NSCLC) treated with ICI. (2) This is an observational, prospective study with 55 NSCLC patients treated with ICI. A total of 43 T and NK cell subsets are analyzed in peripheral blood, including the main markers of exhaustion, differentiation, memory, activation, and inhibition. (3) Regarding the descriptive data, Granzyme B+CD4+ Treg lymphocytes stand out (median 17.4%), and within the NK populations, most patients presented cytotoxic NK cells (CD56+CD3−CD16+GranzymeB+; median 94.8%), and about half of them have highly differentiated adaptive-like NK cells (CD56+CD3−CD16+CD57+ (mean 59.8%). A statistically significant difference was observed between the expression of PD1 within the CD56bright NK cell subpopulation (CD56+CD3−CD16−PD-1+) (p = 0.047) and a better OS. (4) Circulating immune cell subpopulations are promising prognostic biomarkers for ICI. Pending on validation with a larger sample, here we provide an analysis of the major circulating T and NK cell subsets involved in cancer immunity, with promising results despite a small sample size., Work in the JP lab is funded by FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón, Group B29_20R), Grant PID2020-113963RB-I00 by MICIN/AEI, CIBER—Consorcio Centro de Investigación Biomédica en Red—(CIBERINFEC, CB21/13/00087), Grant PTA2019-016739-I funded by MCIN/AEI/10.13039/501100011033 to PD, Instituto de Salud Carlos III, Aspanoa and Carrera de la mujer de Monzón. Grant PID2020-113963RB-I00 by MICIN/AEI to EMGB. Bristol Myers Squibb. Roche Farma S.A. Funders did not make any decisions about the study or the results to post., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The dynamics of neutralizing antibodies against SARS-CoV-2 in cats naturally exposed to virus reveals an increase in antibody activity after re-infection

  • Villanueva-Saz, Sergio
  • Martínez, Mariví
  • Rueda, Pablo
  • Bolea, Sara
  • Pérez, María Dolores
  • Verde, Maite
  • Yzuel, Andrés
  • Hurtado-Guerrero, R.
  • Pardo, Julián
  • Santiago, Llipsy
  • Fernández Casanovas, Antonio
  • Arias, Maykel
1 table., Severe Acute Respiratory Syndrome Coronavirus 2 is the causative agent of Coronavirus Disease 2019 in humans. To date, little is known about the persistence of antibodies against SARS-CoV-2 in animals under natural conditions, in particular susceptible pets such as cat. This study reports the detection and monitoring of the humoral response against SARS-CoV-2 including the detection of immunoglobulins G specific for receptor binding domain of SARS-CoV-2 spike protein by an enzyme-linked immunosorbent assay and neutralizing antibodies by virus neutralization assay. Results showed that these antibodies last longer than 16 months in two naturally apparently healthy infected cats with the absence of clinicopathological findings during the follow-up. Moreover, re-infection is also possible with an important increase in virus neutralization test titers in both animals with no evident systemic signs found during each physical examination and with values of hematologic and biochemical parameters inside the normal reference intervals. Our results confirm a slow but progressive decrease of the kinetics and immunity of neutralizing antibodies in cats after the infection. Furthermore, similar to humans SARS-CoV-2 reinfection can stimulate an increase of the neutralizing antibodies determined by these two serological techniques in domestic cats., RH is supported by ARAID Foundation. Work in the RH laboratory is funded by MCNU (CTQ2013-44367-C2-2-P, BFU2016-75633-P and PID2019-105451GB-I00) and Gobierno de Aragón (E34_R17 and LMP58_18) with FEDER (2014–2020) funds for ‘Building Europe from Aragón’ for financial support. Work in the JP lab is funded by FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón, Group B29_17R), Health National Institute Carlos III (COV20-00308), Aragón Government (Fondo COVID-19), Fundación Santander-Universidad de Zaragoza (Programa COVID-19), grant PID2020-113963RB-I00 by MICIN/AEI and CIBER de Enfermedades Infecciosas. MA and LS have a postdoctoral Juan de la Cierva contract., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CAR Immunotherapy for the treatment of infectious diseases: a systematic review

  • Morte Romea, Elena
  • Pesini, Cecilia
  • Pellejero, Galadriel
  • Martínez-Lostao, Luis
  • Loscos, Silvia
  • Toyas, Carla
  • Redrado, Sergio
  • Dolader, Elena
  • Arias, Maykel
  • Gálvez Buerba, Eva Mª
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
  • Paño, José Ramón
  • Ramírez-Labrada, Ariel
4 figures.-- Supplementary information available., Immunotherapy treatments aim to modulate the host’s immune response to either mitigate it in inflammatory/autoimmune disease or enhance it against infection or cancer. Among different immunotherapies reaching clinical application during the last years, chimeric antigen receptor (CAR) immunotherapy has emerged as an effective treatment for cancer where different CAR T cells have already been approved. Yet their use against infectious diseases is an area still relatively poorly explored, albeit with tremendous potential for research and clinical application. Infectious diseases represent a global health challenge, with the escalating threat of antimicrobial resistance underscoring the need for alternative therapeutic approaches. This review aims to systematically evaluate the current applications of CAR immunotherapy in infectious diseases and discuss its potential for future applications. Notably, CAR cell therapies, initially developed for cancer treatment, are gaining recognition as potential remedies for infectious diseases. The review sheds light on significant progress in CAR T cell therapy directed at viral and opportunistic fungal infections., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Work in the JP laboratory is funded by CIBER -Consorcio Centro de Investigación Biomédica en Red-(CB21/13/00087), Instituto de Salud Carlos III, FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_23R, and LMP139_21), Grant PID2020-113963RB-I00 by MCIN/AEI/10.13039/501100011033, ASPANOA, and Carrera de la Mujer de Monzón. Contrato Ramon y Cajal RYC2022-036627-I (AR-L), Postdoctoral Juan de la Cierva Contract (MA and LS), Predoctoral Grant for Ibero-Americas in Doctoral studies University of Zaragoza-Santander University (ACP), and Predoctoral Grant from AECC (CP). Fundación Científica Asociación Española Contra el Cáncer (AECC) (CP), Río Hortega contrat, Instituto de Salud Carlos III, Post physician specialization, Instituto de Investigación Sanitaria IIS Aragón., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multiparametric in vitro and in vivo analysis of the safety profile of self-assembling peptides

  • Ramírez-Labrada, Ariel
  • Santiago, Llipsy
  • Pesini, Cecilia
  • Arrieta, Marta
  • Arias, Maykel
  • Calvo Pérez, Adanays
  • Ciulla, Maria Gessica
  • Forouharshad, Mahdi
  • Pardo, Julián
  • Gálvez Buerba, Eva Mª
  • Gelain, Fabrizio
10 figures.-- Supplementary information available., Self-assembling peptides (SAPs) have gained significant attention in biomedicine because of their unique properties and ability to undergo molecular self-assembly driven by non-covalent interactions. By manipulating their composition and structure, SAPs can form well-ordered nanostructures with enhanced selectivity, stability and biocompatibility. SAPs offer advantages such as high chemical and biological diversity and the potential for functionalization. However, studies concerning its potentially toxic effects are very scarce, a limitation that compromises its potential translation to humans. This study investigates the potentially toxic effects of six different SAP formulations composed of natural amino acids designed for nervous tissue engineering and amenable to ready cross-linking boosting their biomechanical properties. All methods were performed in accordance with the relevant guidelines and regulations. A wound-healing assay was performed to evaluate how SAPs modify cell migration. The results in vitro demonstrated that SAPs did not induce genotoxicity neither skin sensitization. In vivo, SAPs were well-tolerated without any signs of acute systemic toxicity. Interestingly, SAPs were found to promote the migration of endothelial, macrophage, fibroblast, and neuronal-like cells in vitro, supporting a high potential for tissue regeneration. These findings contribute to the development and translation of SAP-based biomaterials for biomedical applications., The authors gratefully acknowledge the support by INAIL (BRIC2019-ID25) and by the Italian Ministry of Health (Ricerca Corrente 2022–2024), and by the “5X1000” voluntary contributions. Work in the JP laboratory is funded by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB21/13/00087), Instituto de Salud Carlos III, FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragon (Group B29_23R, and LMP139_21), Grant PID2020-113963RBI00 by MCIN/AEI/https://doi.org/10.13039/501100011033, ASPANOA, and Carrera de la Mujer de Monzon. Contrato Ramon y Cajal RYC2022-036627-I (AR-L), Postdoctoral Juan de la Cierva Contract (MA and LS), Predoctoral Grant for Ibero-Americas in Doctoral studies University of Zaragoza-Santander University (ACP) and Predoctoral Grant from AECC (CP).; Fundacion Cientifica Asociacion Espanola Contra el Cancer., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Granzyme-A deficiency attenuates experimental osteoarthritis in mice, but perforin deficiency does not

  • Calvo Ibar, Jorge
  • Santiago, Llipsy
  • Arias, Maykel
  • Pardo, Julián
  • Albareda, Jorge
  • Martínez-Lostao, Luis
  • García-Alvarez, Felícito
[Objectives]: This study aims to assess the development of osteoarthritis (OA) in granzyme A- (gzmA) and B- (gzmB) and perforin- (perf) knockout mice., [Materials and methods]: A total of 75 male and female C57BL/6 (eight to nine-week-old) mice were allocated to: gzmA-deficient (gzmA-/-) (11 females, 8 males), gzmB-deficient (gzmB-/-) (9 females, 8 males), perf-deficient (perf-/-) (10 females, 9 males), and control group (10 females, 10 males). Osteoarthritis was induced in the right knee by instability of the meniscus medial ligament. Sham surgery was practiced in the left knee. Knee samples obtained eight weeks after surgery were stained (Safranin-O) and blindly scored in lateral and medial femur and tibia using the Osteoarthritis Research Society International scale (OARSI) (from Grade 0, cartilage intact to 6, deformation), (five stages from 0, no OA to 4, >50% surface involvement); OARSI score (grade x stage); and a semi-quantitative scale from Grade 0 (normal) to 6 (cartilage erosion >80%)., [Results]: Significantly higher values in all scales in the right knees compared to the left knees in male and female mice were observed (p<0.05). Males of all strains showed in the right knee higher values than females on all scales. Deficiency of perforin did not modify OA severity in any sex. The gzmA-/- females presented less degenerative changes than the other groups., [Conclusion]: Our study results show that sex plays an important role in the development of experimental OA in mice. Deficiency of gzmA can protect from the development of OA in female mice., The authors would like to thank the Servicios Científico Técnicos (IACS) and Servicio de Apoyo a la Investigación (Universidad de Zaragoza). Work in the JP laboratory is funded by the FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón, Group B29_2R), grant PID2020-113963RBI00 by MICIN/AEI and CIBER -Consorcio Centro de Investigación Biomédica en Red- (CIBERINFEC, CB21/13/00087), Instituto de Salud Carlos III. LS is supported by a PhD fellowship (FPI) and by a postdoctoral fellowship 'Juan de la Cierva- Formación from the Ministry of Science, Innovation and Universities MA is supported by a postdoctoral fellowship 'Juan de la Cierva incorporacion' from the Ministry of Science, Innovation and Universities., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs

  • Martínez-Domínguez, Samuel J.
  • García-Mateo, Sandrfa
  • Sainz-Arnal, Pilar
  • Martínez-García, Javier
  • Gallego-Llera, Beatriz
  • Lozano-Limones, María Jesús
  • Hidalgo, Sandra
  • Gargallo-Puyuelo, Carla J.
  • Latre-Santos, Marta
  • Lourdes Nocito-Colon, Maria Mercedes
  • Martínez-Lostao, Luis
  • Refaie, Engy
  • Arroyo-Villarino, Maria Teresa
  • Rio-Nechaevsky, Marcela del
  • Ramírez-Labrada, Ariel
  • Pardo, Julián
  • Gomollón, Fernando
  • Baptista, Pedro M.
Suboptimal vaccine response is a significant concern in patients with Inflammatory Bowel Disease (IBD) receiving biologic drugs. This single-center observational study involved 754 patients with IBD. In Phase I (October 2020-April 2021), 754 IBD participants who had not previously received the SARS-CoV-2 vaccine, underwent blood extraction to assess the seroprevalence of SARS-CoV-2 infection and IBD-related factors. Phase II (May 2021-October 2021) included a subgroup of 52 IBD participants with confirmed previous SARS-CoV-2 infection, who were studied for humoral and cellular response to the SARS-CoV-2 vaccine. In Phase I, treatment with anti-TNF was associated with lower rates of seroconversion (aOR 0.25 95% CI [0.10–0.61]). In Phase II, a significant increase in post-vaccination IgG levels was observed regardless of biologic treatment. However, patients treated with anti-TNF exhibited significantly lower IgG levels compared to those without IBD therapy (5.32 ± 2.47 vs. 7.99 ± 2.59 U/ml, p = 0.042). Following vaccination, a lymphocyte, monocyte, and NK cell activation pattern was observed, with no significant differences between patients receiving biologic drugs and those without IBD treatment. Despite lower seroprevalence and humoral response to the SARS-CoV-2 vaccine in patients treated with anti-TNF, the cellular response to the vaccine did not differ significantly from that patients without IBD therapy., Tis project has been funded by Diputación General de Aragón (DGACOVID-02). Work in the JP laboratory is funded by FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón (Group B29_17R), CIBER INFEC (CB21/13/00087), Ministerio de Ciencia, Innovación y Universidades (MCNU), Agencia Estatal de Investigación (PID2020-113963RBI00), Fundación Inocente Inocente, AECC (Asociación Española Contra el Cáncer), ASPANOA and Carrera de la Mujer de Monzón., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biomarkers of immunotherapy response in patients with non-small-cell lung cancer: microbiota composition, short-chain fatty acids, and intestinal permeability

  • Moratiel-Pellitero, Alba
  • Zapata, María
  • Gascón, Marta
  • Sesma, Andrea
  • Quílez, Elisa
  • Ramírez-Labrada, Ariel
  • Martínez Lostao, Luis
  • Domingo, María Pilar
  • Esteban, Patricia
  • Yubero, Alfonso
  • Barbero-Herranz, Raquel
  • Moreno Blanco, Ana
  • Paño, José Ramón
  • Lastra, Rodrigo
  • Pardo, Julián
  • Isla, Dolores
  • Campo, Rosa del
  • Gálvez Buerba, Eva Mª
5 figures, 1 table., There is evidence of the influence of the intestinal microbiota on the response to immunotherapy in cancer. In addition, we lack markers of response to treatment and toxicity, which obliges us to continue our search for them. In this work, we recruited patients with non-small-cell lung cancer receiving immunotherapy who contributed a fecal and blood sample. We analyzed the possible relationship between the response to immune checkpoint inhibitors and the occurrence of immune-related adverse events, the composition (16S rDNA amplification) and functionality (abundance of short-chain fatty acids) of the gut microbiota, and intestinal membrane permeability as a human factor. No correlations were detected between analytical markers and clinical evolution, with a marked individuality of the gut microbiota in terms of composition, but homogeneity in its functionality and permeability. Immune checkpoint inhibitors have been proposed as the standard treatment for different stages of non-small-cell lung cancer in multiple indications. Not all patients benefit from these treatments, however, and certain patients develop immune-related adverse events. Although the search for predictors of response to these drugs is a major field of research, these issues have yet to be resolved. It has been postulated that microbiota could play a relevant role in conditioning the response to cancer treatments; however, the human factor of intestinal permeability also needs to be considered as it is closely related to the regulation of host–microbiota interaction. In this article, we analyzed the possible relationship between the response to immune checkpoint inhibitors and the onset of immune-related adverse events, gut microbiota status, and intestinal membrane permeability. In a pioneering step, we also measured short-chain fatty acid content in feces. Although the correlation analyses failed to identify predictive biomarkers, even when all variables were integrated, our patients’ microbial gut ecosystems were rich and diverse, and the intestinal barrier’s integrity was preserved. These results add new knowledge on the composition of microbiota and its correlation with barrier permeability and short-chain fatty acids and suggest that more studies are required before these potential biomarkers can be incorporated into the clinical management of patients via immune checkpoint inhibitor treatment., This study was supported by CIBER—Consorcio Centro de Investigación Biomédica en Red—(CB 2021); Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU; FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_23R); Ministerio de Ciencia, Innovación e Universidades (MCNU); and Agencia Estatal de Investigación (PID2020-113963RB-I00). It was also supported by a Personalized and Precision Medicine grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and funded by NextGenerationEU funds from the European Union that finance the actions of the Resilience and Recovery Facility., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Selective detection of active extracellular granzyme A by using a novel fluorescent immunoprobe with application to inflammatory diseases

  • Senán Salinas, Ana
  • Comas, Laura
  • Esteban, Patricia
  • Garzón, Marcela
  • Cheng, Zhiming
  • Santiago, Llipsy
  • Domingo, María Pilar
  • Ramírez-Labrada, Ariel
  • Paño, José Ramón
  • Vendrell, Marc
  • Pardo, Julián
  • Arias, Maykel
  • Gálvez Buerba, Eva Mª
8 figures.-- Supplementary information available., Granzymes (Gzms), a family of serine proteases, expressed by immune and nonimmune cells, present perforin-dependent and independent intracellular and extracellular functions. When released in the extracellular space, GzmA, with trypsin-like activity, is involved in the pathophysiology of different inflammatory diseases. However, there are no validated specific systems to detect active forms of extracellular GzmA, making it difficult to assess its biological relevance and potential use as a biomarker. Here, we have developed fluorescence-energy resonance-transfer (FRET)-based peptide probes (FAM-peptide-DABCYL) to specifically detect GzmA activity in tissue samples and biological fluids in both mouse and human samples during inflammatory diseases. An initial probe was developed and incubated with GzmA and different proteases like GzmB and others with similar cleavage specificity as GzmA like GzmK, thrombin, trypsin, kallikrein, or plasmin. After measuring fluorescence, the probe showed very good specificity and sensitivity for human and mouse GzmA when compared to GzmB, its closest homologue GzmK, and with thrombin. The specificity of this probe was further refined by incubating the samples in a coated plate with a GzmA-specific antibody before adding the probe. The results show a high specific detection of soluble GzmA even when compared with other soluble proteases with very similar cleavage specificity like thrombin, GzmK, trypsin, kallikrein, or plasmin, which shows nearly no fluorescence signal. The high specific detection of GzmA was validated, showing that using pure proteins and serum and tissue samples from GzmA-deficient mice presented a significant reduction in the signal compared with WT mice. The utility of this system in humans was confirmed, showing that GzmA activity was significantly higher in serum samples from septic patients in comparison with healthy donors. Our results present a new immunoprobe with utility to detect extracellular GzmA activity in different biological fluids, confirming the presence of active forms of the soluble protease in vivo during inflammatory and infectious diseases., This research was supported by CIBER─Consorcio Centro de Investigación Biomédica en Red─CIBERINFEC (CB21-13-0087), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea─NextGenerationEU, FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_23R and LMP139_21), Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (PID2020-113963RB-I00, SAF2017-83120-C2-1-R). A.S.-S. was supported by a PhD fellowship from the Aragon Government. M.A. acknowledges funds from the Ministry of Economy and Competitiveness, Spain (FJCI-2017-31629, IJC2019-039192-I). M.V. acknowledges funds from an ERC Consolidator Grant (DYNAFLUORS, 771443), and this project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement (859908)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanobody based immunotherapy for the treatment of invasive fungal infections

  • Sánchez-Martínez, Diego
  • Redrado, Sergio
  • Dolader, Elena
  • Macías León, Javier
  • Domingo, María Pilar
  • Esteban, Patricia
  • Arias, Maykel
  • Ramírez-Labrada, Ariel
  • Hurtado-Guerrero, R.
  • Pardo, Julián
  • Gálvez Buerba, Eva Mª
Work presented at 16.as Jornada de Formación CIBERES-CIBERINFEC del Centro de Investigación Biomédica en Red (CIBERES), 15th-16th june 2023, Madrid (Spain).-- 77. CIBERINFEC Communications., The invasive fungal infections ratios of mortality are between 25% and 70% depending on the type of microorganism and the population at risk, affecting mostly immunocompromised patients. Aspergillus spp. and Cryptococcus spp. are two of the main responsible for these infections. The late non-specific diagnosis and the increasing resistance of the strains highlight the importance of finding new therapeutic alternatives., Gobierno de Aragón, Group B29_20R LMP139_21, FEDER (Fondo Europeo de Desarrollo Regional) Ministerio de Ciencia, Innovación y Universidades (MCNU), Agencia Estatal de Investigación (PID2020-113963RB-I00), CIBERINFEC, Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación and Unión Europea-Next- GenerationEU., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer

  • Zapata, María
  • Moratiel-Pellitero, Alba
  • Isla, Dolores
  • Gálvez Buerba, Eva Mª
  • Gascón, Marta
  • Sesma, Andrea
  • Barbero-Herranz, Raquel
  • Galeano, Javier
  • Campo, Rosa del
  • Ocáriz, Maitane
  • Quílez, Elisa
  • Cruellas, Mara
  • Ramírez-Labrada, Ariel
  • Pardo, Julián
  • Martínez Lostao, Luis
  • Domingo, María Pilar
  • Esteban, Patricia
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Paño, José Ramón
  • Lastra, Rodrigo
8 figures, 2 tables., Lung cancer is a leading cause of morbidity and mortality globally, with its high mortality rate attributed mainly to non-small cell lung cancer (NSCLC). Although immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized its treatment, patient response is highly variable and lacking predictive markers. We conducted a prospective study on 55 patients with NSCLC undergoing ICI therapy to identify predictive markers of both response and immune-related adverse events (IrAEs) in the airway microbiota. We also analyzed the clinical evolution and overall survival (OS) with respect to treatments that affect the integrity of the microbiota, such as antibiotics and corticosteroids. Our results demonstrated that respiratory microbiota differ significantly in ICI responders: they have higher alpha diversity values and lower abundance of the Firmicutes phylum and the Streptococcus genus. Employing a logistic regression model, the abundance of Gemella was the major predictor of non-ICI response, whereas Lachnoanaerobaculum was the best predictor of a positive response to ICI. The most relevant results were that antibiotic consumption is linked to a lower ICI response, and the use of corticosteroids correlated with poorer overall survival. Whereas previous studies have focused on gut microbiota, our findings highlight the importance of the respiratory microbiota in predicting the treatment response. Future research should explore microbiota modulation strategies to enhance immunotherapy outcomes. Understanding the impact of antibiotics, corticosteroids, and microbiota on NSCLC immunotherapy will help personalize treatment and improve patient outcomes., This research was supported by CIBER - Consorcio Centro de Investigación Biomédica en Red - (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU, FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_23R), Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (PID2020-113963RB-I00). It was also supported by a Personalized and Precision Medicine grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, funded by NextGenerationEU funds from the European Union that finance the actions of the Resilience and Recovery Facility., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peripheral blood TCRβ repertoire, IL15, IL2 and soluble ligands for NKG2D activating receptor predict efficacy of immune checkpoint inhibitors in lung cancer

  • Sesma, Andrea
  • Pardo, Julián
  • Isla, Dolores
  • Gálvez Buerba, Eva Mª
  • Gascón, Marta
  • Martínez-Lostao, Luis
  • Moratiel-Pellitero, Alba
  • Paño, José Ramón
  • Quílez, Elisa
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Zapata, María
  • Domingo, María Pilar
  • Esteban, Patricia
  • Sanz-Pamplona, Rebeca
  • Lastra, Rodrigo
  • Ramírez-Labrada, Ariel
4 figures, 5 tables., The development of immune checkpoint inhibitors (ICIs) has changed the therapeutic paradigm of lung cancer (LC), becoming the standard of treatment for previously untreated advanced non-small cell lung cancer (NSCLC) without actionable mutations. It has allowed the achievement of durable responses and resulted in significant survival benefits. However, not all patients respond; hence, molecular biomarkers are needed to help us predict which patients will respond. With this objective, a prospective observational study was designed, including a cohort of 55 patients with NSCLC who received ICIs. We studied whether biomarkers such as TCRβ and specific cytokines involved in the regulation of T cell activity were related to the immunotherapy response. In the survival analysis, it was found that patients with higher TCRβ clonality, lower TCRβ evenness, higher TCRβ Shannon diversity and lower TCRβ convergence had higher overall survival (OS) and progression-free survival (PFS). However, no statistically significant association was observed. Regarding cytokines, those patients with higher levels of IL-2 and IL-15 presented statistically significantly shorter OS and PFS, respectively. In fact, in the multivariable analysis, the high IL-15 level increased the risk of death by three times. Although the sample size was small and more studies are needed to confirm our results, our study reveals promising markers of responses to ICIs., Work in the JP lab is funded by FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón, Group B29_20R), Grant PID2020-113963RB-I00 by MICIN/AEI, CIBER—Consorcio Centro de Investigación Biomédica en Red—(CIBERINFEC, CB21/13/00087), Grant PTA2019-016739-I funded by MCIN/AEI/10.13039/501100011033 to PD, Instituto de Salud Carlos III, Aspanoa and Carrera de la mujer de Monzón. Grant PID2020-113963RB-I00 by MICIN/AEI to EMGB. Contrato Ramón y Cajal RYC2022-036627-I (AR-L). Bristol Myers Squibb. Roche Farma S.A., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

  • Pesini, Cecilia
  • Artal Cortés, Laura
  • Paúl Bernal, Jorge
  • Sánchez Martínez, Diego
  • Ramírez-Labrada, Ariel
3 figures, 1 table., Natural killer (NK) cells play a crucial role in antitumoral and antiviral responses. Yet, cancer cells can alter themselves or the microenvironment through the secretion of cytokines or other factors, hindering NK cell activation and promoting a less cytotoxic phenotype. These resistance mechanisms, often referred to as the “hallmarks of cancer” are significantly influenced by the activation of oncogenes, impacting most, if not all, of the described hallmarks. Along with oncogenes, other types of genes, the tumor suppressor genes are frequently mutated or modified during cancer. Traditionally, these genes have been associated with uncontrollable tumor growth and apoptosis resistance. Recent evidence suggests oncogenic mutations extend beyond modulating cell death/proliferation programs, influencing cancer immunosurveillance. While T cells have been more studied, the results obtained highlight NK cells as emerging key protagonists for enhancing tumor cell elimination by modulating oncogenic activity. A few recent studies highlight the crucial role of oncogenic mutations in NK cell-mediated cancer recognition, impacting angiogenesis, stress ligands, and signaling balance within the tumor microenvironment. This review will critically examine recent discoveries correlating oncogenic mutations to NK cell-mediated cancer immunosurveillance, a relatively underexplored area, particularly in the era dominated by immune checkpoint inhibitors and CAR-T cells. Building on these insights, we will explore opportunities to improve NK cell-based immunotherapies, which are increasingly recognized as promising alternatives for treating low-antigenic tumors, offering significant advantages in terms of safety and manufacturing suitability., Work in the laboratory is funded by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB21/13/00087), Instituto de Salud Carlos III, FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_23R), Ministerio de Ciencia, Innovación e Universidades (MICIU); and Agencia Estatal de Investigación (PID2020-113963RB-I00), ASPANOA, and Carrera de la Mujer de Monzón. DSM received funding from “Grant PID2022-136554OA-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU”. Contrato Ramón y Cajal RYC2022-036627-I (AR-L), Predoctoral Grant from Fundación Científica Asociación Española Contra el Cáncer (CP) and Becas de introducción a la investigación JAEICU_24_00214 (LA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms

  • Pesini, Cecilia
  • Gil Bellido, Mario
  • Millan, Lorena S.
  • Oñate, Carmen
  • Calvo Pérez, Adanays
  • Santiago, Llipsy
  • Iglesias, Eldris
  • Bernal, Jorge Paúl
  • Araujo-Voces, Miguel
  • Paz Artigas, Laura
  • García-Martínez, Laura
  • Roig, Francisco J.
  • Movilla, Nieves
  • García-Aznar, José Manuel
  • Olave, María Teresa
  • Azaceta, Gemma
  • Garrote, Marta
  • Alvarez-Larrán, A.
  • Gálvez Buerba, Eva Mª
  • Sánchez Martínez, Diego
  • Arias, Maykel
  • Pardo, Julián
  • Ramírez-Labrada, Ariel
6 figures., [Background] The adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), lack effective treatment options. Some of these neoplasms are marked by a recurrent mutation that results in the expression of mutant calreticulin (mCALR), a neoantigen absent in healthy tissues, making it a highly specific and appealing target for CAR-T cell therapy., [Methods] Five distinct CARs were designed based on available monoclonal antibody sequences that target mCALR and were subsequently used to generate CAR-T cells. The most effective construct was selected through functional in vitro assays against mCALR-positive cell lines. Its efficacy was then evaluated in cell lines, patient-derived cells, and orthotopic xenograft models, assessing tumor burden, CAR-T cell infiltration, and animal survival. Bulk and single-cell RNA sequencing were performed on patient-derived cells and residual tumor cells from CART-treated mice, respectively, to investigate potential resistance mechanisms. The impact of the most relevant pathway alteration on CAR-T efficacy was also analyzed. Pharmacological rescue assays using targeted agents were then conducted., [Results] Among the five constructs, one demonstrated superior and specific cytotoxicity against mCALR-expressing cells, with no activity against mCALR-negative controls. This CAR-T cell also eliminated patient-derived MPN cells and controlled disease progression in xenograft models, which correlated with the persistence of CAR-T cells and tumor infiltration. Transcriptomic profiling of patient samples and residual tumor cells in spleens of treated mice revealed upregulation of anti-apoptotic proteins. Functional assays confirmed reduced CAR-T efficacy in Bcl-2 high cells, which was restored by co-treatment with venetoclax, indicating a viable combination approach to overcome resistance., [Conclusions] This study demonstrates, for the first time, the successful targeting of mCALR with CAR-T cells as a therapeutic strategy for MPNs. The chosen construct shows strong preclinical efficacy against established cell lines and patient-derived cells. Additionally, transcriptomic profiling uncovered apoptosis resistance mechanisms and supports a combination strategy with BH3 mimetics, such as venetoclax. These findings provide a compelling rationale for ongoing preclinical development and future clinical application of anti-mCALR CAR-T cells for the treatment of MPNs., This work was funded by the Instituto de Salud Carlos III (ISCIII) through the Strategic Action in Health (AES), 2025 call, Health R&D Projects – Strategic Lines of Health Research (project/grant number: PI25/00236). AR-L is funded by a Ramón y Cajal contract (RYC2022-036627-I), financed by MCIN/AEI/10.13039/501100011033 and the European Social Fund (ESF) “Investing in your future” and ASPANOA. Grant PROY_B61_24 "proyectos de Investigación, desarrollo e innovación (I+D+i) en líneas prioritarias y de carácter multidisciplinar" funded by Gobierno de Aragón to AR-L and DSM. The Instituto de Salud Carlos III (ISCIII) through the Spanish Network of Advanced Therapies (RICORS/TERAV+), project RD24/0014/0015, and co-funded by the European Union (EU) to AR-L, JP, DSM and EMG. Work in the JP laboratory is funded by CIBERINFEC-ConsorcioCentro de Investigación Biomédica en Red- (CB21/13/00087), CERTERA andTERAV+ from Institutode Salud Carlos III, FEDER (Fondo Europeo de Desarrollo Regional),Gobierno deAragón (Group B29_23R, and LMP139_21), Grants PID2020-113963RBI00 andPID2024-157582OB-I00from MCIN/ AEI/10.13039/501100011033 and private social initiatives(FARO, AECC, Dona Médula, ASPANOA, and Carrera de la Mujer de Monzón No 101018587). Grant PID2022-136554OA-I00 funded by MICIU/AEI 10.13039/501100011033 and the European Regional Development Fund (ERDF)/EU to DSM. Predoctoral Grant for Ibero-Americas in Doctoral studies University of Zaragoza-Santander University (ACP), and Predoctoral Grant from AECC (CP). This work is part of a project that has received funding from the European Research Council (ICoMICS grant agreement No 101018587)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Supplementary files of Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms [dataset]

  • Pesini, Cecilia
  • Gil Bellido, Mario
  • Millan, Lorena S.
  • Oñate, Carmen
  • Calvo Pérez, Adanays
  • Santiago, Llipsy
  • Iglesias, Eldris
  • Bernal, Jorge Paúl
  • Araujo-Voces, Miguel
  • Paz Artigas, Laura
  • García-Martínez, Laura
  • Roig, Francisco J.
  • Movilla, Nieves
  • García-Aznar, José Manuel
  • Olave, María Teresa
  • Azaceta, Gemma
  • Garrote, Marta
  • Alvarez-Larrán, A.
  • Gálvez Buerba, Eva Mª
  • Sánchez Martínez, Diego
  • Arias, Maykel
  • Pardo, Julián
  • Ramírez-Labrada, Ariel
Under a Creative Commons BY - NC 4.0 license.-- Material and methods: Cell lines culture, genetic modifications, and drug treatment. The MARIMO (Acute myeloid leukemia), HEL (Erythroleukaemia cells homozygous for JAK2 V617F mutation), K562 (Chronic myelogenous leukemia, BCR-Abl+), and THP-1 (Acute monocytic leukemia, JAK2 wt) cell lines were cultured in RPMI medium (Sigma-Aldrich). The Steffen Koschmieder laboratory kindly provided the MARIMO cell line after an MTA agreement with the Yuichi Ishikawa laboratory. HEK293T, A549, HepG2, PANC-1, PC-3, MDA-MB-231, and NHCF-v cell lines were cultured in DMEM (Sigma-Aldrich). Mediums were supplemented with 10% fetal bovine serum (FBS, Capricorn Scientific) and 1% penicillin/streptomycin (Pen/Strep, Sigma-Aldrich). HEL, K562, and THP-1 tumor cell lines were genetically modified to express ZsGreen-FireFly Luciferase (ZsGreen-FFLuc) and mutated calreticulin (mCALR) using lentiviral particles, obtained by co-transfecting HEK293T cells with the psPAX2 (Addgene #12260), the pMD2.G plasmids (Addgene #12259), and the lentiviral interest plasmid (pCCL1 Luc-T2A-ZsGreen and pCCL1 mCALR-T2A-RFP), by using PEI (Sigma-Aldrich). The mCALR sequence identified in the MARIMO cell line (del61), resembling a type 1-like mutation, was used to transduce HEL, K562, and THP-1 cell lines. All resulting cell lines expressed luciferase, ZsGreen (wt), and mCALR-expressing cells (mCALR+) co-expressed RFP protein. Fluorescence-activated cell sorting was used to isolate modified cell populations based on fluorescent protein expression, and mCALR expression was validated by flow cytometry and immunoblotting. Proliferation was evaluated between wild-type and mCAR+ derivative cell lines by Incucyte (Supplementary Figure 2). To knock out mCALR in MARIMO cells, a lentiviral CRISPR/Cas9 system was employed using the lentiCRISPRv2 (Addgene #52961) and lentiGuide-Puro (Addgene #52963) plasmids. A specific single guide RNA (sgRNA) targeting the mCALR was designed following the system requirements and cloned into the BsmBI site of the lentiCRISPRv2 vector following the protocol by Shalem et al. 1. The oligo sequences used were: (oligo 1: CACCGACGAGGAGCAGAGGATGATG, oligo 2:AAACCATCATCCTCTGCTCCTCGTC, Life Technologies). Loss of mutant CALR expression was confirmed by immunoblotting (see below). For venetoclax treatment, the IC50 was determined for each cell line, and a dose below the calculated IC50 was selected for subsequent experiments (Supplementary Figure 15). hiPSC differentiation into cardiomyocytes (hiPSC-CMs) Human induced pluripotent stem cells (hiPSCs; IPSC0028, Sigma-Aldrich) were differentiated into cardiomyocytes. Briefly, hiPSCs were seeded on Matrigel-coated plates (Corning) at a density of 1.5 × 10⁵ cells/cm² in Essential 8 (E8) medium (Gibco). After 48 h, differentiation was induced using RPMI medium (Biowest) supplemented with B27 minus insulin (Gibco) and 9 μM CHIR99021 (Sigma-Aldrich) for 24 h, followed by 48 h in RPMI B27⁻. The medium was then replaced with a 1:1 mixture of conditioned and fresh RPMI B27⁻ containing 5 μM IWP2 (Labclinics) for 48 h, and subsequently with fresh RPMI B27⁻ for an additional 48 h. Cultures were then maintained in RPMI supplemented with B27 plus insulin (RPMI B27⁺) for 72 h. Cardiomyocytes were purified by 48 h incubation in glucose-free RPMI B27⁺ medium (Gibco) and passaged using TrypLE (Gibco). Cells were reseeded on Matrigel-coated plates in RPMI B27⁺ supplemented with 10 μM Y-27632 (Stem Cell Technologies) and 10% KnockOut serum (Gibco). After 24 h, medium was replaced with RPMI B27⁺ containing 2 μM CHIR99021 (expansion medium), refreshed every 48–72 h. Cells were expanded for up to four passages before use. To monitor hiPSC-CM purity, cells were analyzed by flow cytometry after each passage using cardiac Troponin T (cTnT) as a marker. Cells were fixed with 2% paraformaldehyde for 15 min at 4 °C, permeabilized and blocked with 0.1% saponin (MilliporeSigma) and 10% donkey serum (Sigma-Aldrich), and stained with BV421-conjugated anti-cTnT antibody (clone 13-11, BD Biosciences, 1:200). Samples were washed with PBS and analyzed by flow cytometry. Differentiation batches with <80% cTnT⁺ cells were excluded from experiments. Selection of single-chain variable fragment (scFv) and CAR construct design The mutated calreticulin-specific single-chain variable fragments (scFvs) were derived from different previously described antibodies: mCALR-CAR0, from the 8B2-H6 antibody (WO 2016/087514); mCALR-CAR1, from the B3 antibody (WO 2020/175689 A1); mCALR-CAR2, from antibody clone 4; mCALR-CAR3, from antibody clone 74; and mCALR-CAR4, from antibody clone 132 (all from WO 2023/107994, Supplementary Figure 16). The construct included a human CD8 hinge, a human CD8 transmembrane domain, a human 4-1BB endodomain, and the ζ signaling endodomain of the T cell receptor complex (CD3ζ). Additionally, a T2A-enhanced green fluorescent protein (ZsGreen) sequence was incorporated. The construct was synthesized commercially (GenScript) and cloned into a pCCL1 lentiviral backbone. An identical lentiviral vector expressing ZsGreen alone was used as a control (mock) where indicated., Lentiviral Particle Production and T-cell Transduction, Activation, and Expansion To produce viral supernatant, HEK293T cells were co-transfected with the CAR-encoding pCCL1 lentiviral plasmid, the RRE and Rev plasmids, and a plasmid containing the sequence for the VSV-G envelope (kindly provided by Pablo Menéndez’s laboratory). Plasmid transfection was carried out using PEI for 5 hours. Viral supernatants were collected at 48 and 72 hours posttransfection and ultracentrifuged (26000 rpm, 2.5 hours at 4°C, Sorvall WX+, Thermo Scientific). The concentrated supernatant was then titrated in HEK293T cells to determine viral titer for consistent infections. PBMCs were isolated from blood samples of HDs or MPN patients using Ficoll Paque Plus (Merk) gradient centrifugation (PI24/276). Primary human T cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS and 100 U/mL penicillin/streptomycin at 37°C in a 5% CO₂ incubator. T cells were activated using plate-bound anti-CD3 (OKT3) and anti-CD28 (BD Biosciences). After 24 hours, human IL-7 and IL-15 (Miltenyi Biotec) were added at a final concentration of 10 ng/mL. The next day, T cells were seeded into a new plate and transduced with lentiviral CAR vectors at a multiplicity of infection of 30. Proper CAR cell generation was confirmed by eGFP expression and CAR surface expression through extracellular labeling of the scFv using a Biotin-AffiniPure F(ab’)2 Fragment Goat Anti-Mouse IgG (H+L) or Biotin- AffiniPure F(ab’)₂ Fragment Goat Anti-Human IgG (H+L) (Jackson ImmunoResearch Laboratories) followed by incubation with Streptavidin-PE (Miltenyi Biotech) and analyzed by flow cytometry. In Vitro Cytotoxicity Assays and Cytokine Release Determination T cells expressing different CAR-T constructs were co-cultured with target cells at the indicated E:T ratios for 24 to 48 hours to evaluate cytotoxicity. Wells containing only target cells served as controls for normalization. Comparisons were made between mCALR⁺ target cells co-cultured with CAR-transduced T cells and appropriate reference groups, depending on the experimental setup: against mCALR⁻ target cells co-cultured with CAR-T cells or against mCALR+ cells cocultured with non-transduced T cells. Experiments were conducted with a normalized CAR expression level of 35% to compare the different CAR constructs. Cytotoxicity was assessed using both Incucyte-based live-cell imaging and a luciferase-based viability assay. For the Incucyte assays, co-cultures were imaged every 6 hours for up to 48 hours using the Incucyte Live-Cell Analysis System (Sartorius). Red fluorescence intensity was used to quantify target cell survival. Viability was calculated as the percentage of the red fluorescence area relative to control wells at each time point, using the following formula: Viability (%) = (Orange fluorescence area of test wells at t / t₀) / (Orange fluorescence area of control wells at t / t₀) × 100, with analysis performed using Incucyte Analysis Software. In the luciferase-based assay, luciferase activity was measured at 24 and 48 hours post co-culture using D-luciferin (BioVision), and luminescence was recorded with a BioTek Microplate Reader (Agilent). Cell viability was calculated based on the percentage of luminescence relative to control wells using the formula: Viability (%) = (Luminescence of test wells / Luminescence of control wells) × 100. The production of the proinflammatory cytokine interferon-γ (IFN-γ) was measured in cytotoxicity assay supernatants using an enzyme-linked immunosorbent assay (ELISA) from BD Biosciences. Additionally, the multiplex immunoassay quantified TNFα, IL6, IL10, CXCL10, MIP1A/B, IL2, IL13, and IL5 using a customized multiplex immunoassay from R&D Systems, following the manufacturer’s instructions. Flow cytometry Samples were acquired using a MACSQuant® 10 Analyzer Flow Cytometer, a MACSQuant® VYB Flow Cytometer (Miltenyi Biotec), or a BD FACSDiscover™ S8 Cell Sorter (BD Biosciences). For surface staining, cells were resuspended in PBS containing 5% FCS and incubated with the appropriate antibody cocktails and Fcγ Block Reagent (BD Biosciences) for 30 minutes at 4 ºC in the dark. Cells were then washed twice with PBS plus 5% FCS. For intracellular staining, following surface staining, cells were fixed and permeabilized using the FoxP3 Transcription Factor Buffer Kit (Miltenyi Biotec) according to the manufacturer’s protocol, and then incubated with intracellular antibodies for 30 minutes at 4 ºC in the dark. The cell surface expression of mutated calreticulin was detected using an anti-human mutated calreticulin antibody (CAL2 clone, Dianova), followed by an Alexa Fluor-633 secondary antibody (ThermoFisher). All the antibodies used are presented in Supplementary Table 4. The immunophenotyping of healthy donor PBMCs, patient PBMCs, and CD34+ progenitor cells was analyzed using Kaluza Software (Beckman Coulter). The hCD3 phenotyping samples from mice were analyzed using FlowJo™ Software. First, dimensionality reduction was performed using t-SNE. Subsequently, the FlowSOM algorithm was applied to the t-SNE data to conduct unsupervised clustering, enabling the identification of distinct cellular subsets based on phenotypic profiles. Western blot analysis Whole-cell extracts were prepared by lysing cells for 15 min on ice in RIPA lysis buffer (Sigma-Aldrich) supplemented with protease and phosphatase cocktail inhibitors (Roche). Protein concentration in cell lysates was quantified by Bradford (BioRad) using a BioTek Microplate Reader. Cell culture supernatants were centrifuged using a 50 kDa Amicon filter (Sigma-Aldrich) to concentrate mCALR. Whole-cell lysates and cell culture supernatants were separated through SDS-polyacrylamide gels and transferred to a nitrocellulose membrane (BioRad). Membranes were blocked with 5% milk powder in 0.1% Tween 20 (Sigma-Aldrich) in PBS (PBS-T) for 1 h at RT, followed by incubation with primary antibodies diluted in 2.5% milk PBS-T. Western Blotting Luminol Reagent (Thermoscience) was used to detect protein expression with light-sensitive films (Phenix Research). The following antibodies were used: Anti-mCALR (1:500, Dianova), anti-Bcl-2 (1:250, SantaCruz), anti-Bcl-xL (1:1000, CellSignaling) and anti-GAPDH (1:1000, SantaCruz). Xenograft in vivo model. Nonobese diabetic B-NDG mice (female, 5-week-old, Inotiv) were housed in sterile facilities for immunosuppressed animals at the Center for Biomedical Research of Aragon (CIBA). Animal protocols were approved by the University of Zaragoza’s Advisory Ethics Commission for Animal Research (code PI48/23). Mice were IV transplanted with 3×105 Luc/ZsGreen–expressing HEL mCALR+ cells or MARIMO cell line. Two days later, 5×106 CART3-mCALR for eGFP-transfected (MOCK) T cells were i.v. infused. Tumour burden was followed by bioluminescence using the IVIS system (IVIS Lumina XRMS In Vivo Imaging System). To measure tumor burden, mice were injected intraperitoneally with 150 mg/kg of D-luciferin, and luminescence was monitored at the indicated time points. Signal intensity was quantified as total flux (photons/sec/cm²/sr) using Living Image software (PerkinElmer). Mice were regularly examined for weight loss, signs of stress, or the development of hind limb paralysis and euthanized according to preset criteria. Peripheral blood was collected weekly from the submandibular vein and samples were stained for flow cytometry to assess tumor burden (hCD33⁺GFP⁺/total cells) and the human T cells (hCD45⁺hCD3⁺/total cells) and CART3-mCALR cells (hCD45⁺ hCD3⁺ GFP⁺/total cells) persistence with total cells defined as the sum of hCD45⁺ and mCD45⁺ cells in each sample (Antibody information in supplementary Table 4). Red blood cells were lysed with ACK buffer (ThermoFisher). Similarly, spleen, blood, and bone marrow at euthanization were analysed by flow cytometry. Additionally, ex vivo bioluminescence imaging was performed on harvested mouse organs using the IVIS system. For survival analysis, animals were monitored daily and euthanized upon reaching predefined humane endpoints. CAR-treated mice were sacrificed seven days after the death of the last control animal, corresponding to approximately 25% longer survival, as established in the experimental design. At the time of euthanasia, spleen, liver, bone marrow, and tumor tissues were collected for the analysis of T-cell migration and tumor burden. In cases where a mouse in the CAR-treated group died before the planned endpoint, the euthanasia of the remaining mice was postponed by an equivalent period (25% of the control group survival) counted from the day of that death. RNA sequencing and data analysis. For bulk RNA-Seq analysis, patient-derived primary CD34+ cells were enriched, as previously indicated. Total RNA was extracted using TRIzol™ Reagent (Invitrogen). Briefly, samples were lysed in TRIzol, mixed with chloroform (PanReac), and centrifuged to separate phases. The aqueous phase was collected, RNA was precipitated with isopropanol (PanReac), washed with 75% ethanol, and resuspended in RNase-free water (Merk). Additional patient data is given in Supplemental Table 3. Total RNA sequencing was performed by CeGaT (Germany) using the WTS Classic service. Briefly, rRNA was depleted, total RNA was analyzed, libraries were prepared, and sequencing was conducted using Illumina sequencing platforms (Read length: 2 x 100 bp, Output: 6 M clusters (10 Gb) per sample). FASTQ files were preprocessed to filter by read length and sequence quality (minimum length of 50 bp) and to exclude reads with excessive ambiguous bases (>15% Ns). This filtering was performed using the Prinseq tool. Control samples correspond to SRR30220813–SRR30220816 from the SRP526030 study. Reads were mapped to the human reference genome (GRCh38.p14 primary assembly) using HISAT2 v2.2.1. Alignment files in SAM format were converted to BAM format using SAMtools v1.21 . Transcript assembly was performed with StringTie v2.2.2, using the GRCh38.113 GTF annotation file from Ensembl. Differential expression analysis was carried out using DESeq2, edgeR, and voom. For single-cell RNA sequencing, cryopreserved cell suspensions were thawed, washed, and resuspended in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), following the guidelines from 10x Genomics (CG000447—Handbook Cell Thawing Protocols for Singlecell Assays, Rev. B). Cell viability and counts were assessed using acridine range/propidium iodide staining and an automated cell counter (Cellaca MX, Cenibra GmbH, Germany). Singlecell suspensions were then loaded onto a Chromium GEM-X Single Cell 3′ chip (10xGenomics), targeting 20,000 cells per sample, and processed using the Chromium Controller with the GEM-X Universal 3′ Gene Expression v4 kit (10x Genomics) according to the manufacturer’s instructions. The resulting libraries were sequenced on a NovaSeq X Plus (Illumina) using a 25B flow cell, achieving an average depth of approximately 40,000 reads per cell. Sequencing data were demultiplexed and processed with Cell Ranger (v9.0.1) using the GRCh38-2024-A reference genome. 15,782 cells were recovered for sample 1 (MARIMO cell line used for infusion) and 13,051 cells for sample 2 (pooled spleen residual tumor cells), with median gene counts of 3,248 and 2,042 per cell, respectively. Filtered feature-barcode matrices were subsequently analyzed in Seurat (v5.1.0). Cells were retained if they expressed between 600 and 6,000 genes per cell and had less than 20% mitochondrial gene content. Batch correction was performed using SCTransform. After quality control and filtering, the final high-quality libraries contained 13,861 (sample 1) and 9,661 (sample 2) cells, each expressing more than 2,000 genes per cell. Principal component analysis (PCA) and Uniform Manifold Approximation and Projection (UMAP) were computed from the top 30 principal components. Clustering was performed using the Louvain algorithm at a resolution of 0.5, and transcriptional clusters were identified using the FindAllMarkers function in Seurat. Cluster annotation was based on the top-ranked marker genes, and gene module scores were computed using the AddModuleScore function. Comparisons between clusters of interest were conducted using the FindMarkers function in Seurat (Wilcoxon rank-sum tests with Bonferroni correction), with the parameters logfc.threshold = 0, min.pct = 0, and min.diff.pct = −Inf to retain all detected features. Filtered differential expression results were subsequently refined using in-house scripts, applying a minimum adjusted p-value of 0.05 and a minimum log₂ fold change of 0.5., Supplementary Table 1. Kinetic binding parameters and functional activity of anti-mCALR antibody clones, as reported in the respective patents; Supplementary Table 2. Clinical characteristics of patients included in cytotoxicity assays; Supplementary Table 3. Clinical characteristics of patients included in the RNA-seq analysis; Supplementary Table 4. List of antibodies.--, Supplementary Figure 1. Surface expression of CART3-mCALR by human scFv labelling detected by flow cytometry in primary T cells; Supplementary Figure 2. Proliferation of wildtype (WT) and mutated Calreticulin (CALR mut) K562, HEL and THP-1 cell lines using IncuCyte live-cell imaging by confluency analysis; Supplementary Figure 3. CART3-mCALR induces higher cytokine secretion levels compared to other constructs, as measured by Luminex of supernatant of a cytotoxicity at 4:1 E:T ratio against K562 cell line; Supplementary Figure 4. CAR-T cell cytotoxicity against cell lines expressing distinct mCALR variants; Supplementary Figure 5. Real-time cytotoxicity assay monitored by IncuCyte confluence analysis in mCALR-negative cell lines and mCALR-positive controls; Supplementary Figure 6. Cytotoxicity of anti-mCALR CAR-T cells against primary cardiomyocytes, cardiac fibroblasts, and PBMCs; Supplementary Figure 7; Supplementary Figure 8; Supplementary Figure 9; Supplementary Figure 10; Supplementary Figure 11; Supplementary Figure 12; Supplementary Figure 13; Supplementary Figure 14; Supplementary Figure 15; Supplementary Figure 16. Sequences of CARs constructs indicating the source patent for each sequence., This work was funded by the Instituto de Salud Carlos III (ISCIII) through the Strategic Action in Health (AES), 2025 call, Health R&D Projects – Strategic Lines of Health Research (project/grant number: PI25/00236). AR-L is funded by a Ramón y Cajal contract (RYC2022-036627-I), financed by MCIN/AEI/10.13039/501100011033 and the European Social Fund (ESF) “Investing in your future” and ASPANOA. Grant PROY_B61_24 "proyectos de Investigación, desarrollo e innovación (I+D+i) en líneas prioritarias y de carácter multidisciplinar" funded by Gobierno de Aragón to AR-L and DSM. The Instituto de Salud Carlos III (ISCIII) through the Spanish Network of Advanced Therapies (RICORS/TERAV+), project RD24/0014/0015, and co-funded by the European Union (EU) to AR-L, JP, DSM and EMG. Work in the JP laboratory is funded by CIBERINFEC-ConsorcioCentro de Investigación Biomédica en Red- (CB21/13/00087), CERTERA andTERAV+ from Institutode Salud Carlos III, FEDER (Fondo Europeo de Desarrollo Regional),Gobierno deAragón (Group B29_23R, and LMP139_21), Grants PID2020-113963RBI00 andPID2024-157582OB-I00from MCIN/ AEI/10.13039/501100011033 and private social initiatives(FARO, AECC, Dona Médula, ASPANOA, and Carrera de la Mujer de Monzón No 101018587). Grant PID2022-136554OA-I00 funded by MICIU/AEI 10.13039/501100011033 and the European Regional Development Fund (ERDF)/EU to DSM. Predoctoral Grant for Ibero-Americas in Doctoral studies University of Zaragoza-Santander University (ACP), and Predoctoral Grant from AECC (CP). This work is part of a project that has received funding from the European Research Council (ICoMICS grant agreement No 101018587).--, Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes

  • Uranga-Murillo, Iratxe
  • Morte, Elena
  • Hidalgo, Sandra
  • Pesini, Cecilia
  • Garcia-Mulero, Sandra
  • Sierra, Jose L.
  • Santiago, Llipsy
  • Arias, Maykel
  • De Miguel, Diego
  • Encabo-Berzosa, Maria Del Mar
  • Gracia-Tello, Borja
  • Sanz-Pamplona, Rebeca
  • Martinez-Lostao, Luis
  • Galvez, Eva M.
  • Paño-Pardo, Jose R.
  • Ramirez-Labrada, Ariel
  • Pardo, Julian
Coronavirus disease 2019 (COVID19), caused by SARS-CoV-2, is a complex disease, with a variety of clinical manifestations ranging from asymptomatic infection or mild cold-like symptoms to more severe cases requiring hospitalization and critical care. The most severe presentations seem to be related with a delayed, deregulated immune response leading to exacerbated inflammation and organ damage with close similarities to sepsis. Methods: In order to improve the understanding on the relation between host immune response and disease course, we have studied the differences in the cellular (monocytes, CD8+ T and NK cells) and soluble (cytokines, chemokines and immunoregulatory ligands) immune response in blood between Healthy Donors (HD), COVID19 and a group of patients with non-COVID19 respiratory tract infections (NON-COV-RTI). In addition, the immune response profile has been analyzed in COVID19 patients according to disease severity. Results: In comparison to HDs and patients with NON-COV-RTI, COVID19 patients show a heterogeneous immune response with the presence of both activated and exhausted CD8+ T and NK cells characterised by the expression of the immune checkpoint LAG3 and the presence of the adaptive NK cell subset. An increased frequency of adaptive NK cells and a reduction of NK cells expressing the activating receptors NKp30 and NKp46 correlated with disease severity. Although both activated and exhausted NK cells expressing LAG3 were increased in moderate/severe cases, unsupervised cell clustering analyses revealed a more complex scenario with single NK cells expressing more than one immune checkpoint (PD1, TIM3 and/or LAG3). A general increased level of inflammatory cytokines and chemokines was found in COVID19 patients, some of which like IL18, IL1RA, IL36B and IL31, IL2, IFN alpha and TNF alpha, CXCL10, CCL2 and CCL8 were able to differentiate between COVID19 and NON-COV-RTI and correlated with bad prognosis (IL2, TNF alpha, IL1RA, CCL2, CXCL10 and CXCL9). Notably, we found that soluble NKG2D ligands from the MIC and ULBPs families were increased in COVID19 compared to NON-COV-RTI and correlated with disease severity. Conclusions: Our results provide a detailed comprehensive analysis of the presence of activated and exhausted CD8+T, NK and monocyte cell subsets as well as extracellular inflammatory factors beyond cytokines/chemokines, specifically associated to COVID19. Importantly, multivariate analysis including clinical, demographical and immunological experimental variables have allowed us to reveal specific immune signatures to i) differentiate COVID19 from other infections and ii) predict disease severity and the risk of death.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Integration of In silico and in vitro analysis of gliotoxin production reveals a narrow range of producing fungal species

  • Redrado, S.
  • Esteban, P.
  • Domingo, M. P.
  • López, C.
  • Rezusta, A.
  • Ramirez-Labrada, A.
  • Arias, M.
  • Pardo, J.
  • Galvez, E. M.
Gliotoxin is a fungal secondary metabolite with impact on health and agriculture since it might act as virulence factor and contaminate human and animal food. Homologous gliotoxin (GT) gene clusters are spread across a number of fungal species although if they produce GT or other related epipolythiodioxopiperazines (ETPs) remains obscure. Using bioinformatic tools, we have identified homologous gli gene clusters similar to the A. fumigatus GT gene cluster in several fungal species. In silico study led to in vitro confirmation of GT and Bisdethiobis(methylthio)gliotoxin (bmGT) production in fungal strain cultures by HPLC detection. Despite we selected most similar homologous gli gene cluster in 20 different species, GT and bmGT were only detected in section Fumigati species and in a Trichoderma virens Q strain. Our results suggest that in silico gli homology analyses in different fungal strains to predict GT production might be only informative when accompanied by analysis about mycotoxin production in cell cultures.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo

  • Lanuza, P. M.
  • Alonso, M. H.
  • Hidalgo, S.
  • Uranga-Murillo, I.
  • García-Mulero, S.
  • Arnau, R.
  • Santos, C.
  • Sanjuan, X.
  • Santiago, L.
  • Comas, L.
  • Redrado, S.
  • Pazo-Cid, R.
  • Agustin-Ferrández, M. J.
  • Jaime-Sánchez, P.
  • Pesini, C.
  • Gálvez, E. M.
  • Ramírez-Labrada, A.
  • Arias, M.
  • Sanz-Pamplona, R.
  • Pardo Jimeno, J.
Background: Colorectal cancer (CRC) is a heterogeneous disease with variable mutational profile and tumour microenvironment composition that influence tumour progression and response to treatment. While chemoresistant and poorly immunogenic CRC remains a challenge, the development of new strategies guided by biomarkers could help stratify and treat patients. Allogeneic NK cell transfer emerges as an alternative against chemoresistant and poorly immunogenic CRC. Methods: NK cell-related immunological markers were analysed by transcriptomics and immunohistochemistry in human CRC samples and correlated with tumour progression and overall survival. The anti-tumour ability of expanded allogeneic NK cells using a protocol combining cytokines and feeder cells was analysed in vitro and in vivo and correlated with CRC mutational status and the expression of ligands for immune checkpoint (IC) receptors regulating NK cell activity. Results: HLA-I downmodulation and NK cell infiltration correlated with better overall survival in patients with a low-stage (II) microsatellite instability-high (MSI-H) CRC, suggesting a role of HLA-I as a prognosis biomarker and a potential benefit of NK cell immunotherapy. Activated allogeneic NK cells were able to eliminate CRC cultures without PD-1 and TIM-3 restriction but were affected by HLA-I expression. In vivo experiments confirmed the efficacy of the therapy against both HLA+ and HLA- CRC cell lines. Concomitant administration of pembrolizumab failed to improve tumour control. Conclusions: Our results reveal an immunological profile of CRC tumours in which immunogenicity (MSI-H) and immune evasion mechanisms (HLA downmodulation) favour NK cell immunosurveillance at early disease stages. Accordingly, we have shown that allogeneic NK cell therapy can target tumours expressing mutations conferring poor prognosis regardless of the expression of T cell-related inhibitory IC ligands. Overall, this study provides a rationale for a new potential basis for CRC stratification and NK cell-based therapy. Copyright © 2022 Lanuza, Alonso, Hidalgo, Uranga-Murillo, García-Mulero, Arnau, Santos, Sanjuan, Santiago, Comas, Redrado, Pazo-Cid, Agustin-Ferrández, Jaime-Sánchez, Pesini, Gálvez, Ramírez-Labrada, Arias, Sanz-Pamplona and Pardo.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

All about (nk cell-mediated) death in two acts and an unexpected encore: initiation, execution and activation of adaptive immunity

  • Ramírez-Labrada, Ariel
  • Pesini, Cecilia
  • Santiago, Llipsy
  • Hidalgo, Sandra
  • Calvo-Pérez, Adanays
  • Oñate, Carmen
  • Andrés Tovar, A.
  • Garzón-Tituaña, Mar
  • Uranga-Murillo, Iratxe
  • Arias, Maykel A.
  • Galvez, Eva M.
  • Pardo, Julián
NK cells are key mediators of immune cell-mediated cytotoxicity toward infected and transformed cells, being one of the main executors of cell death in the immune system. NK cells recognize target cells through an array of inhibitory and activating receptors for endogenous or exogenous pathogen-derived ligands, which together with adhesion molecules form a structure known as immunological synapse that regulates NK cell effector functions. The main and best characterized mechanisms involved in NK cell-mediated cytotoxicity are the granule exocytosis pathway (perforin/granzymes) and the expression of death ligands. These pathways are recognized as activators of different cell death programmes on the target cells leading to their destruction. However, most studies analyzing these pathways have used pure recombinant or native proteins instead of intact NK cells and, thus, extrapolation of the results to NK cell-mediated cell death might be difficult. Specially, since the activation of granule exocytosis and/or death ligands during NK cell-mediated elimination of target cells might be influenced by the stimulus received from target cells and other microenvironment components, which might affect the cell death pathways activated on target cells. Here we will review and discuss the available experimental evidence on how NK cells kill target cells, with a special focus on the different cell death modalities that have been found to be activated during NK cell-mediated cytotoxicity; including apoptosis and more inflammatory pathways like necroptosis and pyroptosis. In light of this new evidence, we will develop the new concept of cell death induced by NK cells as a new regulatory mechanism linking innate immune response with the activation of tumour adaptive T cell responses, which might be the initiating stimulus that trigger the cancer-immunity cycle. The use of the different cell death pathways and the modulation of the tumour cell molecular machinery regulating them might affect not only tumour cell elimination by NK cells but, in addition, the generation of T cell responses against the tumour that would contribute to efficient tumour elimination and generate cancer immune memory preventing potential recurrences.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Silver nanoparticles–polyethyleneimine-based coatings with antiviral activity against SARS-CoV-2: a new method to functionalize filtration media

  • Baselga, M.
  • Uranga-Murillo, I.
  • de Miguel, D.
  • Arias, M.
  • Sebastián, V.
  • Pardo, J.
  • Arruebo, M.
The use of face masks and air purification systems has been key to curbing the transmission of SARS-CoV-2 aerosols in the context of the current COVID-19 pandemic. However, some masks or air conditioning filtration systems are designed to remove large airborne particles or bacteria from the air, being limited their effectiveness against SARS-CoV-2. Continuous research has been aimed at improving the performance of filter materials through nanotechnology. This article presents a new low-cost method based on electrostatic forces and coordination complex formation to generate antiviral coatings on filter materials using silver nanoparticles and polyethyleneimine. Initially, the AgNPs synthesis procedure was optimized until reaching a particle size of 6.2 ± 2.6 nm, promoting a fast ionic silver release due to its reduced size, obtaining a stable colloid over time and having reduced size polydispersity. The stability of the binding of the AgNPs to the fibers was corroborated using polypropylene, polyester-viscose, and polypropylene-glass spunbond mats as substrates, obtaining very low amounts of detached AgNPs in all cases. Under simulated operational conditions, a material loss less than 1% of nanostructured silver was measured. SEM micrographs demonstrated high silver distribution homogeneity on the polymer fibers. The antiviral coatings were tested against SARS-CoV-2, obtaining inactivation yields greater than 99.9%. We believe our results will be beneficial in the fight against the current COVID-19 pandemic and in controlling other infectious airborne pathogens. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Hemizygous Granzyme A Mice Expressing the hSOD1G93A Transgene Show Slightly Extended Lifespan

  • Moreno-Martinez, Laura
  • Santiago, Llipsy
  • de la Torre, Miriam
  • Calvo, Ana Cristina
  • Pardo, Julián
  • Osta, Rosario
Granzyme A (gzmA), a serine protease involved in the modulation of the inflammatory immune response, is found at an elevated level in the serum from ALS patients. However, the influence of gzmA on the progression of ALS remains unclear. The aim of our work was to assess whether the absence of gzmA in an ALS murine model could help slow down the progression of the disease. Homozygous and hemizygous gzmA-deficient mice expressing the hSOD1G93A transgene were generated, and survival of these mice was monitored. Subsequently, gene and protein expression of inflammatory and oxidative stress markers was measured in the spinal cord and quadriceps of these mice. We observed the longest lifespan in gzmA+/− mice. GzmA gene and protein expression was downregulated in the spinal cord and serum from gmzA+/− mice, confirming that the increased survival of hemizygous mice is correlated with lower levels of gzmA. In addition, mRNA and protein levels of glutathione reductase (GSR), involved in oxidative stress, were found downregulated in the spinal cord and quadriceps of gmzA+/− mice, together with lower IL-1β and IL-6 mRNA levels in hemyzigous mice. In summary, our findings indicate for the first time that reduced levels, but not the absence, of gzmA could slightly ameliorate the disease progression in this animal model.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer

  • Gascón-Ruiz, Marta
  • Ramírez-Labrada, Ariel
  • Lastra, Rodrigo
  • Martínez-Lostao, Luis
  • Paño-Pardo, J. Ramón
  • Sesma, Andrea
  • Zapata-García, María
  • Moratiel, Alba
  • Quílez, Elisa
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Domingo, María Pilar
  • Esteban, Patricia
  • Gálvez, Eva M.
  • Pardo, Julián
  • Isla, Dolores
(1) Despite the effectiveness of immune checkpoint inhibitors (ICIs) in lung cancer, there is a lack of knowledge about predictive biomarkers. The objective of our study is to analyze different subsets of T-lymphocytes and natural killer (NK) cells as predictive biomarkers in a cohort of patients with nonsmall cell lung cancer (NSCLC) treated with ICI. (2) This is an observational, prospective study with 55 NSCLC patients treated with ICI. A total of 43 T and NK cell subsets are analyzed in peripheral blood, including the main markers of exhaustion, differentiation, memory, activation, and inhibition. (3) Regarding the descriptive data, Granzyme B+CD4+ Treg lymphocytes stand out (median 17.4%), and within the NK populations, most patients presented cytotoxic NK cells (CD56+CD3−CD16+GranzymeB+; median 94.8%), and about half of them have highly differentiated adaptive-like NK cells (CD56+CD3−CD16+CD57+ (mean 59.8%). A statistically significant difference was observed between the expression of PD1 within the CD56bright NK cell subpopulation (CD56+CD3−CD16−PD-1+) (p = 0.047) and a better OS. (4) Circulating immune cell subpopulations are promising prognostic biomarkers for ICI. Pending on validation with a larger sample, here we provide an analysis of the major circulating T and NK cell subsets involved in cancer immunity, with promising results despite a small sample size.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study

  • Irún, Pilar
  • Gracia, Rafael
  • Piazuelo, Elena
  • Pardo, Julián
  • Morte, Elena
  • Paño, José Ramon
  • Boza, Julio
  • Carrera-Lasfuentes, Patricia
  • Higuera, Gustavo A.
  • Lanas, Ángel
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is highly heterogeneous, ranging from asymptomatic to severe and fatal cases. COVID-19 has been characterized by an increase of serum pro-inflammatory cytokine levels which seems to be associated with fatal cases. By contrast, the role of pro-resolving lipid mediators (SPMs), involved in the attenuation of inflammatory responses, has been scarcely investigated, so further studies are needed to understand SPMs metabolism in COVID-19 and other infectious diseases. Our aim was to analyse the lipid mediator metabolome, quantifying pro- and anti-inflammatory serum bioactive lipids by LC–MS/MS in 7 non-infected subjects and 24 COVID-19 patients divided into mild, moderate, and severe groups according to the pulmonary involvement, to better understand the disease outcome and the severity of the pulmonary manifestations. Statistical analysis was performed with the R programming language (R Foundation for Statistical Computing, Vienna, Austria). All COVID-19 patients had increased levels of Prostaglandin E2. Severe patients showed a significant increase versus controls, mild- and moderate-affected patients, expressed as median (interquartile range), in resolvin E1 [112.6 (502.7) vs 0.0 (0.0) pg/ml in the other groups], as well as in maresin 2 [14.5 (7.0) vs 8.1 (4.2), 5.5 (4.3), and 3.0 (4.0) pg/ml, respectively]. Moreover, 14-hydroxy docosahexaenoic acid (14-HDHA) levels were also increased in severe vs control and mild-affected patients [24.7 (38.2) vs 2.4 (2.2) and 3.7 (6.4) ng/mL, respectively]. Resolvin D5 was also significantly elevated in both moderate [15.0 (22.4) pg/ml] and severe patients [24.0 (24.1) pg/ml] versus controls [0.0 (0.0) pg/ml]. These results were confirmed by sparse partial least squares discriminant analysis which highlighted the contribution of these mediators to the separation between each of the groups. In conclusion, the potent inflammatory response to SARS-CoV-2 infection involves not only pro- but also anti-inflammatory lipid mediators that can be quantified in easily accessible serum samples, suggesting the need to perform future research on their generation pathways that will help us to discover new therapeutic targets.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Granzyme-A deficiency attenuates experimental osteoarthritis in mice, but perforin deficiency does not

  • Calvo, Jorge
  • Santiago, Llipsy
  • Arias, Maykel
  • Pardo, Julián
  • Albareda, Jorge
  • Martínez-Lostao, Luis
  • García-Alvarez, Felícito
Objectives: This study aims to assess the development of osteoarthritis (OA) in granzyme A- (gzmA) and B- (gzmB) and perforin- (perf) knockout mice. Materials and methods: A total of 75 male and female C57BL/6 (eight to nine-week-old) mice were allocated to: gzmA-deficient (gzmA-/-) (11 females, 8 males), gzmB-deficient (gzmB-/-) (9 females, 8 males), perf-deficient (perf-/-) (10 females, 9 males), and control group (10 females, 10 males). Osteoarthritis was induced in the right knee by instability of the meniscus medial ligament. Sham surgery was practiced in the left knee. Knee samples obtained eight weeks after surgery were stained (Safranin-O) and blindly scored in lateral and medial femur and tibia using the Osteoarthritis Research Society International scale (OARSI) (from Grade 0, cartilage intact to 6, deformation), (five stages from 0, no OA to 4, >50% surface involvement); OARSI score (grade x stage); and a semi-quantitative scale from Grade 0 (normal) to 6 (cartilage erosion >80%). Results: Significantly higher values in all scales in the right knees compared to the left knees in male and female mice were observed (p<0.05). Males of all strains showed in the right knee higher values than females on all scales. Deficiency of perforin did not modify OA severity in any sex. The gzmA-/- females presented less degenerative changes than the other groups. Conclusion: Our study results show that sex plays an important role in the development of experimental OA in mice. Deficiency of gzmA can protect from the development of OA in female mice.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Fluorogenic Granzyme A Substrates Enable Real-Time Imaging of Adaptive Immune Cell Activity

  • Cheng, Zhiming
  • Thompson, Emily J
  • Mendive-Tapia, Lorena
  • Scott, Jamie I
  • Benson, Sam
  • Kitamura, Takanori
  • Senan-Salinas, Ana
  • Samarakoon, Youhani
  • Roberts, Edward W
  • Arias, Maykel A
  • Pardo, Julian
  • Galvez, Eva M
  • Vendrell, Marc
Cytotoxic immune cells, including T lymphocytes (CTLs) and natural killer (NK) cells, are essential components of the host response against tumors. CTLs and NK cells secrete granzyme A (GzmA) upon recognition of cancer cells; however, there are very few tools that can detect physiological levels of active GzmA with high spatiotemporal resolution. Herein, we report the rational design of the near‐infrared fluorogenic substrates for human GzmA and mouse GzmA. These activity‐based probes display very high catalytic efficiency and selectivity over other granzymes, as shown in tissue lysates from wild‐type and GzmA knock‐out mice. Furthermore, we demonstrate that the probes can image how adaptive immune cells respond to antigen‐driven recognition of cancer cells in real time.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs

  • Martínez-Domínguez, Samuel J.
  • García-Mateo, Sandra
  • Sainz-Arnal, Pilar
  • Martínez-García, Javier
  • Gallego-Llera, Beatriz
  • Lozano-Limones, María Jesús
  • Hidalgo, Sandra
  • Gargallo-Puyuelo, Carla J.
  • Latre-Santos, Marta
  • Nocito-Colon, Maria Mercedes Lourdes
  • Martínez-Lostao, Luis
  • Refaie, Engy
  • Arroyo-Villarino, Maria Teresa
  • del Rio-Nechaevsky, Marcela
  • Ramirez-Labrada, Ariel
  • Pardo, Julián
  • Gomollón, Fernando
  • Baptista, Pedro M.
Suboptimal vaccine response is a significant concern in patients with Inflammatory Bowel Disease (IBD) receiving biologic drugs. This single-center observational study involved 754 patients with IBD. In Phase I (October 2020-April 2021), 754 IBD participants who had not previously received the SARS-CoV-2 vaccine, underwent blood extraction to assess the seroprevalence of SARS-CoV-2 infection and IBD-related factors. Phase II (May 2021-October 2021) included a subgroup of 52 IBD participants with confirmed previous SARS-CoV-2 infection, who were studied for humoral and cellular response to the SARS-CoV-2 vaccine. In Phase I, treatment with anti-TNF was associated with lower rates of seroconversion (aOR 0.25 95% CI [0.10–0.61]). In Phase II, a significant increase in post-vaccination IgG levels was observed regardless of biologic treatment. However, patients treated with anti-TNF exhibited significantly lower IgG levels compared to those without IBD therapy (5.32 ± 2.47 vs. 7.99 ± 2.59 U/ml, p = 0.042). Following vaccination, a lymphocyte, monocyte, and NK cell activation pattern was observed, with no significant differences between patients receiving biologic drugs and those without IBD treatment. Despite lower seroprevalence and humoral response to the SARS-CoV-2 vaccine in patients treated with anti-TNF, the cellular response to the vaccine did not differ significantly from that patients without IBD therapy.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

CAR immunotherapy for the treatment of infectious diseases: a systematic review

  • Morte-Romea, Elena
  • Pesini, Cecilia
  • Pellejero-Sagastizábal, Galadriel
  • Letona-Giménez, Santiago
  • Martínez-Lostao, Luis
  • Loscos Aranda, Silvia
  • Toyas, Carla
  • Redrado, Sergio
  • Dolader-Ballesteros, Elena
  • Arias, Maykel
  • Galvez, Eva M.
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
  • Paño-Pardo, Jose Ramón
  • Ramírez-Labrada, Ariel
Immunotherapy treatments aim to modulate the host’s immune response to either mitigate it in inflammatory/autoimmune disease or enhance it against infection or cancer. Among different immunotherapies reaching clinical application during the last years, chimeric antigen receptor (CAR) immunotherapy has emerged as an effective treatment for cancer where different CAR T cells have already been approved. Yet their use against infectious diseases is an area still relatively poorly explored, albeit with tremendous potential for research and clinical application. Infectious diseases represent a global health challenge, with the escalating threat of antimicrobial resistance underscoring the need for alternative therapeutic approaches. This review aims to systematically evaluate the current applications of CAR immunotherapy in infectious diseases and discuss its potential for future applications. Notably, CAR cell therapies, initially developed for cancer treatment, are gaining recognition as potential remedies for infectious diseases. The review sheds light on significant progress in CAR T cell therapy directed at viral and opportunistic fungal infections.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Multiparametric in vitro and in vivo analysis of the safety profile of self-assembling peptides

  • Ramirez-Labrada, Ariel
  • Santiago, Llipsy
  • Pesini, Cecilia
  • Arrieta, Marta
  • Arias, Maykel
  • Calvo Pérez, Adanays
  • Ciulla, Maria Gessica
  • Forouharshad, Mahdi
  • Pardo, Julian
  • Gálvez, Eva M.
  • Gelain, Fabrizio
Self-assembling peptides (SAPs) have gained significant attention in biomedicine because of their unique properties and ability to undergo molecular self-assembly driven by non-covalent interactions. By manipulating their composition and structure, SAPs can form well-ordered nanostructures with enhanced selectivity, stability and biocompatibility. SAPs offer advantages such as high chemical and biological diversity and the potential for functionalization. However, studies concerning its potentially toxic effects are very scarce, a limitation that compromises its potential translation to humans. This study investigates the potentially toxic effects of six different SAP formulations composed of natural amino acids designed for nervous tissue engineering and amenable to ready cross-linking boosting their biomechanical properties. All methods were performed in accordance with the relevant guidelines and regulations. A wound-healing assay was performed to evaluate how SAPs modify cell migration. The results in vitro demonstrated that SAPs did not induce genotoxicity neither skin sensitization. In vivo, SAPs were well-tolerated without any signs of acute systemic toxicity. Interestingly, SAPs were found to promote the migration of endothelial, macrophage, fibroblast, and neuronal-like cells in vitro, supporting a high potential for tissue regeneration. These findings contribute to the development and translation of SAP-based biomaterials for biomedical applications.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Biomarkers of immunotherapy response in patients with non-small-cell lung cancer: microbiota composition, short-chain fatty acids, and intestinal permeability

  • Moratiel-Pellitero, Alba
  • Zapata-García, María
  • Gascón Ruiz, Marta
  • Sesma, Andrea
  • Quílez, Elisa
  • Ramírez-Labrada, Ariel
  • Martínez-Lostao, Luis
  • Domingo, María Pilar
  • Esteban, Patricia
  • Yubero, Alfonso
  • Barbero-Herranz, Raquel
  • Moreno-Blanco, Ana
  • Paño, José Ramón
  • Lastra, Rodrigo
  • Pardo, Julián
  • Isla, Dolores
  • Campo, Rosa del
  • Gálvez, Eva
Immune checkpoint inhibitors have been proposed as the standard treatment for different stages of non-small-cell lung cancer in multiple indications. Not all patients benefit from these treatments, however, and certain patients develop immune-related adverse events. Although the search for predictors of response to these drugs is a major field of research, these issues have yet to be resolved. It has been postulated that microbiota could play a relevant role in conditioning the response to cancer treatments; however, the human factor of intestinal permeability also needs to be considered as it is closely related to the regulation of host–microbiota interaction. In this article, we analyzed the possible relationship between the response to immune checkpoint inhibitors and the onset of immune-related adverse events, gut microbiota status, and intestinal membrane permeability. In a pioneering step, we also measured short-chain fatty acid content in feces. Although the correlation analyses failed to identify predictive biomarkers, even when all variables were integrated, our patients’ microbial gut ecosystems were rich and diverse, and the intestinal barrier’s integrity was preserved. These results add new knowledge on the composition of microbiota and its correlation with barrier permeability and short-chain fatty acids and suggest that more studies are required before these potential biomarkers can be incorporated into the clinical management of patients via immune checkpoint inhibitor treatment.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Identification of FasL as a crucial host factor driving COVID-19 pathology and lethality

  • Albert, Marie-Christine
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • De Miguel, Diego
  • Peña, Natacha
  • Montinaro, Antonella
  • Varanda, Ana Beatriz
  • Theobald, Sebastian J.
  • Areso, Itziar
  • Saggau, Julia
  • Koch, Manuel
  • Liccardi, Gianmaria
  • Peltzer, Nieves
  • Rybniker, Jan
  • Hurtado-Guerrero, Ramón
  • Merino, Pedro
  • Monzón, Marta
  • Badiola, Juan J.
  • Reindl-Schwaighofer, Roman
  • Sanz-Pamplona, Rebeca
  • Cebollada-Solanas, Alberto
  • Megyesfalvi, Zsolt
  • Dome, Balazs
  • Secrier, Maria
  • Hartmann, Boris
  • Bergmann, Michael
  • Pardo, Julián
  • Walczak, Henning
The dysregulated immune response and inflammation resulting in severe COVID-19 are still incompletely understood. Having recently determined that aberrant death-ligand-induced cell death can cause lethal inflammation, we hypothesized that this process might also cause or contribute to inflammatory disease and lung failure following SARS-CoV-2 infection. To test this hypothesis, we developed a novel mouse-adapted SARS-CoV-2 model (MA20) that recapitulates key pathological features of COVID-19. Concomitantly with occurrence of cell death and inflammation, FasL expression was significantly increased on inflammatory monocytic macrophages and NK cells in the lungs of MA20-infected mice. Importantly, therapeutic FasL inhibition markedly increased survival of both, young and old MA20-infected mice coincident with substantially reduced cell death and inflammation in their lungs. Intriguingly, FasL was also increased in the bronchoalveolar lavage fluid of critically-ill COVID-19 patients. Together, these results identify FasL as a crucial host factor driving the immuno-pathology that underlies COVID-19 severity and lethality, and imply that patients with severe COVID-19 may significantly benefit from therapeutic inhibition of FasL.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Selective Detection of Active Extracellular Granzyme A by Using a Novel Fluorescent Immunoprobe with Application to Inflammatory Diseases

  • Senan-Salinas, Ana
  • Comas, Laura
  • Esteban, Patricia
  • Garzón-Tituaña, Marcela
  • Cheng, Zhiming
  • Santiago, Llipsy
  • Domingo, Maria Pilar
  • Ramírez-Labrada, Ariel
  • Paño-Pardo, José Ramón
  • Vendrell, Marc
  • Pardo, Julián
  • Arias, Maykel A.
  • Galvez, Eva M.
Granzymes (Gzms), a family of serine proteases, expressed by immune and nonimmune cells, present perforin-dependent and independent intracellular and extracellular functions. When released in the extracellular space, GzmA, with trypsin-like activity, is involved in the pathophysiology of different inflammatory diseases. However, there are no validated specific systems to detect active forms of extracellular GzmA, making it difficult to assess its biological relevance and potential use as a biomarker. Here, we have developed fluorescence-energy resonance-transfer (FRET)-based peptide probes (FAM-peptide-DABCYL) to specifically detect GzmA activity in tissue samples and biological fluids in both mouse and human samples during inflammatory diseases. An initial probe was developed and incubated with GzmA and different proteases like GzmB and others with similar cleavage specificity as GzmA like GzmK, thrombin, trypsin, kallikrein, or plasmin. After measuring fluorescence, the probe showed very good specificity and sensitivity for human and mouse GzmA when compared to GzmB, its closest homologue GzmK, and with thrombin. The specificity of this probe was further refined by incubating the samples in a coated plate with a GzmA-specific antibody before adding the probe. The results show a high specific detection of soluble GzmA even when compared with other soluble proteases with very similar cleavage specificity like thrombin, GzmK, trypsin, kallikrein, or plasmin, which shows nearly no fluorescence signal. The high specific detection of GzmA was validated, showing that using pure proteins and serum and tissue samples from GzmA-deficient mice presented a significant reduction in the signal compared with WT mice. The utility of this system in humans was confirmed, showing that GzmA activity was significantly higher in serum samples from septic patients in comparison with healthy donors. Our results present a new immunoprobe with utility to detect extracellular GzmA activity in different biological fluids, confirming the presence of active forms of the soluble protease in vivo during inflammatory and infectious diseases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The importance of murine phospho-MLKL-S345 in situ detection for necroptosis assessment in vivo

  • Kelepouras, Konstantinos
  • Saggau, Julia
  • Varanda, Ana Beatriz
  • Zrilic, Matea
  • Kiefer, Christine
  • Rakhsh-Khorshid, Hassan
  • Lisewski, Ina
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • Pardo, Julian
  • Tonnus, Wulf
  • Linkermann, Andreas
  • Annibaldi, Alessandro
  • Walczak, Henning
  • Liccardi, Gianmaria
Necroptosis is a caspase-independent modality of cell death implicated in many inflammatory pathologies. The execution of this pathway requires the formation of a cytosolic platform that comprises RIPK1 and RIPK3 which, in turn, mediates the phosphorylation of the pseudokinase MLKL (S345 in mouse). The activation of this executioner is followed by its oligomerisation and accumulation at the plasma-membrane where it leads to cell death via plasma-membrane destabilisation and consequent permeabilisation. While the biochemical and cellular characterisation of these events have been amply investigated, the study of necroptosis involvement in vivo in animal models is currently limited to the use of Mlkl−/− or Ripk3−/− mice. Yet, even in many of the models in which the involvement of necroptosis in disease aetiology has been genetically demonstrated, the fundamental in vivo characterisation regarding the question as to which tissue(s) and specific cell type(s) therein is/are affected by the pathogenic necroptotic death are missing. Here, we describe and validate an immunohistochemistry and immunofluorescence-based method to reliably detect the phosphorylation of mouse MLKL at serine 345 (pMLKL-S345). We first validate the method using tissues derived from mice in which Caspase-8 (Casp8) or FADD are specifically deleted from keratinocytes, or intestinal epithelial cells, respectively. We next demonstrate the presence of necroptotic activation in the lungs of SARS-CoV-infected mice and in the skin and spleen of mice bearing a Sharpin inactivating mutation. Finally, we exclude necroptosis occurrence in the intestines of mice subjected to TNF-induced septic shock. Importantly, by directly comparing the staining of pMLKL-345 with that of cleaved Caspase-3 staining in some of these models, we identify spatio-temporal and functional differences between necroptosis and apoptosis supporting a role of RIPK3 in inflammation independently of MLKL versus the role of RIPK3 in activation of necroptosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

An agent-based method to estimate 3D cell migration trajectories from 2D measurements: Quantifying and comparing T vs CAR-T 3D cell migration

  • Camacho-Gómez, Daniel
  • Movilla, Nieves
  • Borau, Carlos
  • Martín, Alejandro
  • Oñate Salafranca, Carmen
  • Pardo, Julián
  • Gómez-Benito, María José
  • García-Aznar, José Manuel
Background and objective: Immune cell migration is one of the key features that enable immune cells to find invading pathogens, control tissue damage, and eliminate primary developing tumors. Chimeric antigen receptor (CAR) T-cell therapy is a novel strategy in the battle against various cancers. It has been successful in treating hematological tumors, yet it still faces many challenges in the case of solid tumors. In this work, we evaluate the three-dimensional (3D) migration capacity of T and CAR-T cells within dense collagen-based hydrogels. Quantifying three-dimensional (3D) cell migration requires microscopy techniques that may not be readily accessible. Thus, we introduce a straightforward mathematical model designed to infer 3D trajectories of cells from two-dimensional (2D) cell trajectories. Methods: We develop a 3D agent-based model (ABM) that simulates the temporal changes in the direction of migration with an inverse transform sampling method. Then, we propose an optimization procedure to accurately orient cell migration over time to reproduce cell migration from 2D experimental cell trajectories. With this model, we simulate cell migration assays of T and CAR-T cells in microfluidic devices conducted under hydrogels with different concentrations of type I collagen and validate our 3D cell migration predictions with light-sheet microscopy. Results: Our findings indicate that CAR-T cell migration is more sensitive to collagen concentration increases than T cells, resulting in a more pronounced reduction in their invasiveness. Moreover, our computational model reveals significant differences in 3D movement patterns between T and CAR-T cells. T cells exhibit migratory behavior in 3D whereas that CAR-T cells predominantly move within the plane, with limited movement in the direction. However, upon the introduction of a CXCL12 chemical gradient, CAR-T cells present migration patterns that closely resemble those of T cells. Conclusions: This framework demonstrates that 2D projections of 3D trajectories may not accurately represent real migration patterns. Moreover, it offers a tool to estimate 3D migration patterns from 2D experimental data, which can be easily obtained with automatic quantification algorithms. This approach helps reduce the need for sophisticated and expensive microscopy equipment required in laboratories, as well as the computational burden involved in producing and analyzing 3D experimental data.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Reseña (Review)

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

  • Pesini, Cecilia
  • Artal, Laura
  • Paúl Bernal, Jorge
  • Sánchez Martinez, Diego
  • Pardo, Julián
  • Ramírez-Labrada, Ariel
Natural killer (NK) cells play a crucial role in antitumoral and antiviral responses. Yet, cancer cells can alter themselves or the microenvironment through the secretion of cytokines or other factors, hindering NK cell activation and promoting a less cytotoxic phenotype. These resistance mechanisms, often referred to as the “hallmarks of cancer” are significantly influenced by the activation of oncogenes, impacting most, if not all, of the described hallmarks. Along with oncogenes, other types of genes, the tumor suppressor genes are frequently mutated or modified during cancer. Traditionally, these genes have been associated with uncontrollable tumor growth and apoptosis resistance. Recent evidence suggests oncogenic mutations extend beyond modulating cell death/proliferation programs, influencing cancer immunosurveillance. While T cells have been more studied, the results obtained highlight NK cells as emerging key protagonists for enhancing tumor cell elimination by modulating oncogenic activity. A few recent studies highlight the crucial role of oncogenic mutations in NK cell-mediated cancer recognition, impacting angiogenesis, stress ligands, and signaling balance within the tumor microenvironment. This review will critically examine recent discoveries correlating oncogenic mutations to NK cell-mediated cancer immunosurveillance, a relatively underexplored area, particularly in the era dominated by immune checkpoint inhibitors and CAR-T cells. Building on these insights, we will explore opportunities to improve NK cell-based immunotherapies, which are increasingly recognized as promising alternatives for treating low-antigenic tumors, offering significant advantages in terms of safety and manufacturing suitability.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Distinct cell death pathways induced by granzymes collectively protect against intestinal Salmonella infection

  • Chawla, Amanpreet Singh
  • Vandereyken, Maud
  • Arias, Maykel
  • Santiago, Llipsy
  • Dikovskaya, Dina
  • Nguyen, Chi
  • Skariah, Neema
  • Wenner, Nicolas
  • Golovchenko, Natasha B.
  • Thomson, Sarah J.
  • Ondari, Edna
  • Garzón-Tituaña, Marcela
  • Anderson, Christopher J.
  • Bergkessel, Megan
  • C. D. Hinton, Jay
  • Edelblum, Karen L.
  • Pardo, Julian
  • Swamy, Mahima
Intestinal intraepithelial T lymphocytes (IEL) constitutively express high amounts of the cytotoxic proteases Granzymes (Gzm) A and B and are therefore thought to protect the intestinal epithelium against infection by killing infected epithelial cells. However, the role of IEL granzymes in a protective immune response has yet to be demonstrated. We show that GzmA and GzmB are required to protect mice against oral, but not intravenous, infection with Salmonella enterica serovar Typhimurium, consistent with an intestine-specific role. IEL-intrinsic granzymes mediate the protective effects by controlling intracellular bacterial growth and aiding in cell-intrinsic pyroptotic cell death of epithelial cells. Surprisingly, we found that both granzymes play non-redundant roles. GzmB-/- mice carried significantly lower burdens of Salmonella, as predominant GzmA-mediated cell death effectively reduced bacterial translocation across the intestinal barrier. Conversely, in GzmA-/- mice, GzmB-driven apoptosis favored luminal Salmonella growth by providing nutrients, while still reducing translocation across the epithelial barrier. Together, the concerted actions of both GzmA and GzmB balance cell death mechanisms at the intestinal epithelium to provide optimal control that Salmonella cannot subvert.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Peripheral Blood TCRß Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung Cancer

  • Sesma, Andrea
  • Pardo, Julian
  • Isla, Dolores
  • M. Gálvez, Eva
  • Gascón-Ruiz, Marta
  • Martínez-Lostao, Luis
  • Moratiel, Alba
  • Paño-Pardo, J. Ramón
  • Quílez, Elisa
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Zapata-García, María
  • Domingo, María Pilar
  • Esteban, Patricia
  • Sanz Pamplona, Rebeca
  • Lastra, Rodrigo
  • Ramírez-Labrada, Ariel
The development of immune checkpoint inhibitors (ICIs) has changed the therapeutic paradigm of lung cancer (LC), becoming the standard of treatment for previously untreated advanced non-small cell lung cancer (NSCLC) without actionable mutations. It has allowed the achievement of durable responses and resulted in significant survival benefits. However, not all patients respond; hence, molecular biomarkers are needed to help us predict which patients will respond. With this objective, a prospective observational study was designed, including a cohort of 55 patients with NSCLC who received ICIs. We studied whether biomarkers such as TCRβ and specific cytokines involved in the regulation of T cell activity were related to the immunotherapy response. In the survival analysis, it was found that patients with higher TCRβ clonality, lower TCRβ evenness, higher TCRβ Shannon diversity and lower TCRβ convergence had higher overall survival (OS) and progression-free survival (PFS). However, no statistically significant association was observed. Regarding cytokines, those patients with higher levels of IL-2 and IL-15 presented statistically significantly shorter OS and PFS, respectively. In fact, in the multivariable analysis, the high IL-15 level increased the risk of death by three times. Although the sample size was small and more studies are needed to confirm our results, our study reveals promising markers of responses to ICIs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants

  • Conde E.
  • Vercher E.
  • Soria-Castellano M.
  • Suarez-Olmos J.
  • Mancheno U.
  • Elizalde E.
  • Rodriguez M.L.
  • Glez-Vaz J.
  • Casares N.
  • Rodriguez-Garcia E.
  • Hommel M.
  • Gonzalez-Aseguinolaza G.
  • Uranga-Murillo I.
  • Pardo J.
  • Alkorta G.
  • Melero I.
  • Lasarte J.
  • Hervas-Stubbs S.
Background Target antigen (Ag) loss has emerged as a major cause of relapse after chimeric antigen receptor T (CART)-cell therapy. We reasoned that the combination of CART cells, with the consequent tumor debulking and release of Ags, together with an immunomodulatory agent, such as the stimulator of interferon gene ligand (STING-L) 2'3'-cyclic GMP-AMP (2'3'-cGAMP), may facilitate the activation of an endogenous response to secondary tumor Ags able to counteract this tumor escape mechanism. Methods Mice bearing B16-derived tumors expressing prostate-specific membrane Ag or gp75 were treated systemically with cognate CART cells followed by intratumoral injections of 2'3'-cGAMP. We studied the target Ag inmunoediting by CART cells and the effect of the CART/STING-L combination on the control of STING-L-treated and STING-L-non-treated tumors and on the endogenous antitumor T-cell response. The role of Batf3-dependent dendritic cells (DCs), stimulator of interferon gene (STING) signaling and perforin (Perf)-mediated killing in the efficacy of the combination were analyzed. Results Using an immune-competent solid tumor model, we showed that CART cells led to the emergence of tumor cells that lose the target Ag, recreating the cancer immunoediting effect of CART-cell therapy. In this setting, the CART/STING-L combination, but not the monotherapy with CART cells or STING-L, restrained tumor progression and enhanced overall survival, showing abscopal effects on distal STING-L-non-treated tumors. Interestingly, a secondary immune response against non-chimeric antigen receptor-targeted Ags (epitope spreading), as determined by major histocompatibility complex-I-tetramer staining, was fostered and its intensity correlated with the efficacy of the combination. This was consistent with the oligoclonal expansion of host T cells, as revealed by in-depth T-cell receptor repertoire analysis. Moreover, only in the combination group did the activation of endogenous T cells translate into a systemic antitumor response. Importantly, the epitope spreading and the antitumor effects of the combination were fully dependent on host STING signaling and Batf3-dependent DCs, and were partially dependent on Perf release by CART cells. Interestingly, the efficacy of the CART/STING-L treatment also depended on STING signaling in CART cells. Conclusions Our data show that 2'3'-cGAMP is a suitable adjuvant to combine with CART-cell therapy, allowing the induction of an endogenous T-cell response that prevents the outgrowth of Ag-loss tumor variants.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Biological relevance of Granzymes A and K during E. coli sepsis

  • Uranga-Murillo I.
  • Tapia E.
  • Garzón-Tituaña M.
  • Ramirez-Labrada A.
  • Santiago L.
  • Pesini C.
  • Esteban P.
  • Roig F.J.
  • Galvez E.M.
  • Bird P.I.
  • Pardo Jimeno, J.
  • Arias M.
Aims: Recent in vitro findings suggest that the serine protease Granzyme K (GzmK) may act as a proinflammatory mediator. However, its role in sepsis is unknown. Here we aim to understand the role of GzmK in a mouse model of bacterial sepsis and compare it to the biological relevance of Granzyme A (GzmA). Methods: Sepsis was induced in WT, GzmA-/- and GzmK-/- mice by an intraperitoneal injection of 2x108 CFU from E. coli. Mouse survival was monitored during 5 days. Levels of IL-1a, IL-1ß, TNFa and IL-6 in plasma were measured and bacterial load in blood, liver and spleen was analyzed. Finally, profile of cellular expression of GzmA and GzmK was analyzed by FACS. Results: GzmA and GzmK are not involved in the control of bacterial infection. However, GzmA and GzmK deficient mice showed a lower sepsis score in comparison with WT mice, although only GzmA deficient mice exhibited increased survival. GzmA deficient mice also showed reduced expression of some proinflammatory cytokines like IL1-a, IL-ß and IL-6. A similar result was found when extracellular GzmA was therapeutically inhibited in WT mice using serpinb6b, which improved survival and reduced IL-6 expression. Mechanistically, active extracellular GzmA induces the production of IL-6 in macrophages by a mechanism dependent on TLR4 and MyD88. Conclusions: These results suggest that although both proteases contribute to the clinical signs of E. coli-induced sepsis, inhibition of GzmA is sufficient to reduce inflammation and improve survival irrespectively of the presence of other inflammatory granzymes, like GzmK.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Inflammatory cell death induced by cytotoxic lymphocytes: a dangerous but necessary liaison

  • de Miguel D.
  • Ramirez-Labrada A.
  • Uranga I.
  • Hidalgo S.
  • Santiago L.
  • Galvez E.M.
  • Arias M.
  • Pardo J.
Cytotoxic lymphocytes (CLs), and more specifically Tc and NK cells, are the main executors of cell death in the immune system, playing a key role during both immunosurveillance and immunotherapy. These cells induce regulated cell death (RCD) by different mechanisms, being granular exocytosis and expression of death ligands the most prominent and best characterized ones. Apoptosis, a traditionally considered low-inflammatory type of cell death, has been accepted for years as the paradigm of RCD induced by CLs. However, several recent studies have demonstrated that NK cells and Tc cells can also induce more inflammatory forms of cell death, namely, necroptosis, pyroptosis, and ferroptosis. Activation of these highly inflammatory types of cell death appears to critically contribute to the activation of a successful antitumour immune response. Additionally, the role of specific cell death pathways in immunogenic cell death is still under intense debate, especially considering the interconnections with other inflammatory forms of cell death. These evidences, together with the advent of new cancer immunotherapies, highlight the necessity to deepen our understanding of the link between the cell death triggered by CLs and inflammation. This knowledge will be instrumental to maximize the antitumour potential of immunotherapies, minimizing deleterious effects associated with these treatments. In this review, we will briefly summarize the main features of apoptosis, necroptosis, pyroptosis and ferroptosis, to subsequently discuss the most recent evidences about the role of these RCD pathways during the elimination of cancer cells mediated by CLs and its modulation to increase the efficacy of cancer immunotherapy.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFß and activin A suppression

  • Rea, Anna
  • Santana-Hernández, Sara
  • Villanueva, Javier
  • Sanvicente-García, Marta
  • Cabo, Mariona
  • Suárez-Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Torralba-Raga, Lamberto
  • Pérez, Lorena
  • Bhattarai, Bishan
  • Alari-Pahissa, Elisenda
  • Georgoudaki, Anna-Maria
  • Balaguer, Francesc
  • Juan, Manel
  • Pardo, Julián
  • Celià-Terrassa, Toni
  • Rovira, Ana
  • Möker, Nina
  • Zhang, Congcong
  • Colonna, Marco
  • Spanholtz, Jan
  • Malmberg, Karl-Johan
  • Montagut, Clara
  • Albanell, Joan
  • Güell, Marc
  • López-Botet
  • Muntasell, Aura
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR–Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4KO NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4KO NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4KO conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C

  • Mata, Elena
  • Broset, Esther
  • Matute, Carlos
  • Stoian, Andrei
  • Adame, Susana
  • Alejo, Teresa
  • López, Alexandre
  • Andrés, Beatriz
  • Heredero, Juan
  • de Miguel, Diego
  • Giménez-Warren, Javier
  • Lampaya, Verónica
  • Casabona, Diego
  • Calvo, Alba
  • Quincoces, Gema
  • Peñuelas, Iván
  • Gamazo, Carlos
  • Uranga, Iratxe
  • Peña, Natacha
  • Arias, Maykel
  • Pardo, Julián
  • Moreno, Bernardino
  • Badiola, Juan
  • Martínez-Oliván, Juan
  • Pérez-Herrán, Esther
mRNA vaccines have shown great efficacy against SARS-CoV-2, yet challenges remain in optimizing vaccine components to achieve enhanced immune response and vaccine stability. In this study, we developed CPVax-CoV, a new lyophilized mRNA vaccine that features novel thiolactone-based ionizable lipids and newly designed untranslated regions (UTRs) for enhanced expression. Incorporation of these optimized components into our vaccine candidate CPVax-CoV significantly improved immune responses in mice compared to commercially available mRNA vaccines. Moreover, lyophilized CPVax-CoV has proven to be thermostable, maintaining its biological activity for up to one year at 4 °C and 25 °C after lyophilization, overcoming the cold-chain limitations of current mRNA vaccines. This vaccine demonstrates protective efficacy against ancestral SARS-CoV-2 and the Omicron XBB variant, offering a scalable solution for global distribution and pandemic preparedness. These findings underscore the potential of this platform for future next-generation mRNA vaccine development.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms

  • Pesini, Cecilia
  • Gil-Bellido, Mario
  • Millán, Lorena S.
  • Oñate, Carmen
  • Calvo-Pérez, Adanays
  • Santiago, Llipsy
  • Iglesias, Eldris
  • Bernal, Jorge Paúl
  • Araujo-Voces, Miguel
  • Paz Artigas, Laura
  • García-Martínez, Laura
  • Roig, Francisco J
  • Movilla Meno, Nieves
  • Garcia-Aznar, José Manuel
  • Menéndez-Jandula, Bárbara
  • Olave, María Teresa
  • Azaceta Reinares, Gemma
  • Garrote, Marta
  • Alvarez-Larrán, Alberto
  • Gálvez, Eva M
  • Sánchez Martínez, Diego
  • Arias, Maykel A
  • Pardo, Julian
  • Ramirez-Labrada, Ariel
Background The adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), lack effective treatment options. Some of these neoplasms are marked by a recurrent mutation that results in the expression of mutant calreticulin (mCALR), a neoantigen absent in healthy tissues, making it a highly specific and appealing target for CAR-T cell therapy. Methods Five distinct CARs were designed based on available monoclonal antibody sequences that target mCALR and were subsequently used to generate CAR-T cells. The most effective construct was selected through functional in vitro assays against mCALR-positive cell lines. Its efficacy was then evaluated in cell lines, patient-derived cells, and orthotopic xenograft models, assessing tumor burden, CAR-T cell infiltration, and animal survival. Bulk and single-cell RNA sequencing were performed on patient-derived cells and residual tumor cells from CART-treated mice, respectively, to investigate potential resistance mechanisms. The impact of the most relevant pathway alteration on CAR-T efficacy was also analyzed. Pharmacological rescue assays using targeted agents were then conducted. Results Among the five constructs, one demonstrated superior and specific cytotoxicity against mCALR-expressing cells, with no activity against mCALR-negative controls. This CAR-T cell also eliminated patient-derived MPN cells and controlled disease progression in xenograft models, which correlated with the persistence of CAR-T cells and tumor infiltration. Transcriptomic profiling of patient samples and residual tumor cells in spleens of treated mice revealed upregulation of anti-apoptotic proteins. Functional assays confirmed reduced CAR-T efficacy in Bcl-2 high cells, which was restored by co-treatment with venetoclax, indicating a viable combination approach to overcome resistance. Conclusions This study demonstrates, for the first time, the successful targeting of mCALR with CAR-T cells as a therapeutic strategy for MPNs. The chosen construct shows strong preclinical efficacy against established cell lines and patient-derived cells. Additionally, transcriptomic profiling uncovered apoptosis resistance mechanisms and supports a combination strategy with BH3 mimetics, such as venetoclax. These findings provide a compelling rationale for ongoing preclinical development and future clinical application of anti-mCALR CAR-T cells for the treatment of MPNs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Lysine-11 ubiquitination drives type-I/III interferon induction by cGAS–STING and Toll-like receptors 3 and 4

  • Betrancourt, Alexis
  • Cinko, M. Talha
  • Varanda, Ana Beatriz
  • Arias, Maykel
  • Uranga-Murillo, Iratxe
  • Peña, Natacha
  • Kaps, Lucia-Maria
  • Chau, Long Fung
  • Buratti, Bianca
  • Brägelmann, Johannes
  • de Miguel, Diego
  • Becker, Kerstin
  • Casper, Ramona
  • Martin, Rocio
  • Alcami, Antonio
  • Ferguson, Brian J.
  • Pardo, Julian
  • Rieser, Eva
  • Walczak, Henning
Pattern recognition receptor (PRR)-induced interferon (IFN) is critical for effective immunity. The PRRs Toll-like receptor (TLR) 3, TLR4 and cyclic GMP–AMP synthase (cGAS), together with the stimulator of IFN genes (STING), signal through TANK-binding kinase 1 (TBK1), which activates the type-I/III IFN-inducing transcription factor interferon-response factor 3 (IRF3). The mechanism by which these PRRs activate TBK1 remains unresolved. Here we show that lysine-11 (K11)-linked ubiquitination drives TBK1 activation by these PRRs. The E3 ligase ANKIB1 attaches K11-linked ubiquitin chains to components of the TLR3- and cGAS–STING-induced signalosomes. This facilitates Optineurin recruitment to these complexes, in turn enabling recruitment and activation of TBK1 and IRF3, defining an uncharacterized signalling axis. In mice, ANKIB1 deficiency dampens IFN induction via TLR3 and cGAS–STING, reducing interferonopathy and compromising protection against HSV-1, respectively. Together, our results demonstrate an unanticipated and critical role for ANKIB1-generated K11-linked ubiquitination in the immune response activated by cGAS–STING, TLR3 and TLR4.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity

  • Marco, Sonia
  • Fernández, Myriam
  • Honorato, Beatriz
  • Juanarena, Nerea
  • Sainz, Cristina
  • Andueza, Ainhoa
  • Gould, David J.
  • Anderson, Seth
  • de Andrea, Carlos
  • Domínguez, Paulo Pérez
  • Wong, Paolo
  • Vásquez, Carlos
  • Narinda, Irene
  • Unzu, Carmen
  • Isola, Sergio
  • Tavira, Beatriz
  • Ariz, Mikel
  • Camps, Gracián
  • Sanmamed, Miguel F.
  • Pardo, Julián
  • Labiano, Sara
  • Alonso, Marta M.
  • Marco-Sanz, Javier
  • Guruceaga, Elizabeth
  • Collantes, María
  • Simón, Jon Ander
  • Peñuelas, Iván
  • Fernández-Irigoyen, Joaquín
  • Santamaría, Enrique
  • Prieto, Jesús
  • Dubrot, Juan
Radiotherapy (RT) can prime the immune system against cancer but often fails to generate effective antitumor responses due to concomitant induction of immunosuppressive factors. To overcome this limitation, we built upon the observation that RT enhances adeno-associated vectors (AAVs) tumor transduction through the epigenetic modification of vector episomes. We designed an AAV-based platform to deliver immunostimulatory cytokines through an interferon (IFN)-inducible promoter that allows for spatial control of transgene expression into irradiated tumors. As opposed to a constitutive system, local delivery of a vector encoding for inducible IL-12 (AAV-iIL12) achieves an efficient production of the cytokine without significant toxicity. Combination of RT and AAV-iIL12 generates a highly immunostimulatory tumor microenvironment (TME) leading to robust local and systemic antitumor responses in an IFNγ- and FAS-dependent manner, able to overcome common immune-evasion mechanisms. Our work shows that radiation coupled with AAV-based immune-gene delivery is an efficient and safe approach to treat cancer.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity

  • Marco, Sonia
  • Fernández-Sendin, Myriam
  • Honorato, Beatriz
  • Juanarena, Nerea
  • Sáinz, Cristina
  • Andueza San Miguel, Ainhoa
  • Gould, David J.
  • Anderson, Seth
  • Andrea, Carlos de
  • Pérez Domínguez, Paulo
  • Wong, Paolo
  • Vásquez, Carlos
  • Narinda, Irene
  • Unzu, Carmen
  • Isola, Sergio
  • Tavira, Beatriz
  • Ariz Galilea, Mikel
  • Camps, Gracián
  • Sanmamed, Miguel F.
  • Pardo, Julián
  • Labiano, Sara
  • Alonso, Marta M.
  • Marco-Sanz, Javier
  • Guruceaga, Elizabeth
  • Collantes, María
  • Simón, Jon Ander
  • Peñuelas, Iván
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Prieto, Jesús
  • Dubrot, Juan
Radiotherapy (RT) can prime the immune system against cancer but often fails to generate effective antitumor responses due to concomitant induction of immunosuppressive factors. To overcome this limitation, we built upon the observation that RT enhances adeno-associated vectors (AAVs) tumor transduction through the epigenetic modification of vector episomes. We designed an AAV-based platform to deliver immunostimulatory cytokines through an interferon (IFN)-inducible promoter that allows for spatial control of transgene expression into irradiated tumors. As opposed to a constitutive system, local delivery of a vector encoding for inducible IL-12 (AAV-iIL12) achieves an efficient production of the cytokine without significant toxicity. Combination of RT and AAV-iIL12 generates a highly immunostimulatory tumor microenvironment (TME) leading to robust local and systemic antitumor responses in an IFNγ- and FAS-dependent manner, able to overcome common immune-evasion mechanisms. Our work shows that radiation coupled with AAV-based immune-gene delivery is an efficient and safe approach to treat cancer., This work was supported by grants PID2024-160227OB-I00 (funded by MICIU/AEI/10.13039/501100011033 and FEDER, EU), NAIARA Project (ref. 0011-1411-2025-000144, funded by Gobierno de Navarra and FEDER 2021-2027), PID2020-113963RBI00 from AEI, Aragon Government (B29-20R) and CIBERINFEC/Instituto de Salud Carlos III, (CB21/13/00087).